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ABSTRACT OF DISSERTATION

CERAMIDE-ENRICHED EXTRACELLULAR VESICLES: A ROLE IN ENHANCING
AMYLOID-BETA NEUROTOXICITY AND MITOCHONDRIAL DAMAGE IN
ALZHEIMER’S DISEASE
Alzheimer’s disease (AD) is an age-dependent, progressive, neurodegenerative
disorder that is characterized clinically by the impairment of cognitive functions
concomitant with behavioral and personality changes. AD is associated with distinct
pathological hallmarks, namely, intracellular neurofibrillary tangles comprised of
hyperphosphorylated tau protein, extracellular amyloid beta (Aβ) plaques, and marked
brain atrophy. Besides their main role as the core component of amyloid plaques,
oligomeric Aβ have been shown to be neurotoxic. The exact mechanism of Aβ
neurotoxicity is yet to be elucidated.
Recently, a pathogenic function of small extracellular vesicles- also known as
exosomes- has been proposed, suggesting that exosomes can transfer pathogens between
cells. One such pathogen that exploits this pathway is Aβ in Alzheimer’s disease, however,
it is not known yet whether this Aβ/exosomes association would affect the neuronal toxicity
of Aβ.
Exosomes are nano-sized lipid vesicles that are formed by inward budding of late
endosomes to form multi vesicular bodies (MVB) which fuse to the plasma membrane and
release exosomes to the extracellular space. Exosomes serve as a means of intercellular
communication due to their ability in carrying cargoes including microRNA (miRNA),
messenger RNA (mRNA), proteins, and other biomolecules. There are several established
pathways for exosomes biogenesis, one of which is triggered by the sphingolipid ceramide.
Ceramide is a key molecule in sphingolipids metabolism and it is involved in several
cellular processes such as proliferation, senescence and apoptosis. It has also been reported
that ceramide levels are elevated in AD patients brain specimens.
Exploiting the fact that exosomes can cross the blood brain barrier we therefore
used serum derived exosomes to study the biophysical and biochemical characteristics of
Alzheimer’s disease mouse model (5xFAD) and AD patients’ exosomes compared to wild
type and healthy individuals. We found that serum from 5xFAD mice and AD patients
contain a subpopulation of astrocyte-derived exosomes that are enriched with ceramide,

particularly C16:0, C18:0, C20:0, 22:0, C24:0, and C24:1 ceramide species. This
subpopulation (termed astrosomes) was shown to associated with Aβ and are prone to
aggregation as confirmed by nanoparticle tracking and cluster analyses. To study the
functional characteristics of these Aβ-associated astrosomes, we used Neuro-2a (N2a)
cells, human iPS cell-derived neurons, and mouse primary cultured neurons as in vitro
tissue culture models. When taken up by neurons, Aβ-associated astrosomes were
specifically transported to mitochondria where they induced mitochondria clustering,
evident by elevation of expression of the fission protein dynamin related protein1 (Drp1).
Aβ-associated astrosomes, but not wild type or healthy control human exosomes, mediated
binding of Aβ to voltage-dependent anion channel 1 (VDAC1), a gate keeper protein in the
outer mitochondrial membrane that is involved in regulating passage of metabolites,
nucleotides, and ions; it plays a crucial role in regulating apoptosis. This Aβ/VDAC1
interaction leads to caspase activation and subsequently apoptosis. Interestingly, removing
the ceramide-enriched astrosomes from the exosome pool using lipid-mediated affinity
chromatography (LIMAC) mitigated that toxic effect on neurons. These results were
replicated using brain derived exosomes.
To investigate the in vivo significance of our in vitro results, we stereotaxically
injected wild type mice (two weeks old) with 5xFAD or wild type brain derived exosomes
(nine months old). We found that within two days, the injected exosomes were specifically
taken up by neurons and transported to mitochondria. Consistent with our in vitro data
using Aβ-associated astrosomes, the exosomes isolated from 5xFAD brain, but not those
from wild type brain, induced complex formation of Aβ with VDAC1 and activation of
caspase 3.
To test that our observations hold true in physiological conditions, we generated a
novel astrosome reporter mouse model. This was accomplished by crossing of Aldh1l1Cre/ERT with floxed CD63-GFP and 5xFAD mice (5XFAD xAldh1l1-Cre/ERTxCD63GFPfl/fl) which allows us to track astrosome uptake and their subsequent effects. As seen
with the injected exosomes, we found that endogenous GFP-labeled astrosomes are taken
up by neurons where they shuttle Aβ and induce mitotoxicity.
In conclusion, our data show that association of Aβ to astrosomes in critical for Aβ
neurotoxicity. Therefore, we discovered a novel mechanism by which Aβ induces AD
neuropathology as well as potential pharmacological target.
KEYWORDS: Alzheimer’s disease, exosomes, ceramide, astrocytes, sphingolipids.
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CHAPTER 1. INTRODUCTION
1.1

Alzheimer’s Disease
1.1.1

Background

Dementia is a general term that encompasses a severe set of symptoms which can
interfere with a person’s daily life and activities [1]. These symptoms include thinking and
social abilities as well as changes in memory. Furthermore, dementia could result in a
functional decline in memory, visual perception, language skills, self-management,
problem solving, and one’s ability to focus or pay attention [2].
Dementia comprises a wide array of specific medical conditions, rather than one
sole entity. There are several causes of dementia including vascular cognitive impairment,
dementia with Lewy bodies, Frontotemporal dementia, and Parkinson's disease [2, 3].
Alzheimer’s disease (AD) accounts for 60-80% of all dementia cases [4]. Alois Alzheimer,
a German psychiatrist, presented the first signature case of AD, in 1906, at the 37th
convention of Southwestern German Psychiatrist [5]. The disease did not coin the name
“Alzheimer’s” until 1910, when Emil Kraepelin, a coworker of Alois Alzheimer, named
the disease after him in honor of his achievements.
Despite the heterogeneity of AD symptoms among patients, the most common
initial symptom is a gradual worsening ability to remember new information. Other
common cognitive related symptoms include memory loss that results in daily life
disturbance, struggle with words in speaking or writing, challenges in planning or solving
problems, misplacing things and losing the ability to retrace steps, and not being able to
complete familiar tasks at home, at work or at leisure[4, 6]. The list of symptoms can occur
in unison with confusion, involving time and place, and difficulty understanding visual
1

images and spatial relationships. AD patients suffer from non-cognitive symptoms as well.
These symptoms include, but are not limited to, decreased or poor judgment, sudden
changes in mood and personality, trouble keeping up with social activities, increased
anxiety, agitation, and sleep disturbances.
With respect to diagnosis, there is currently no distinct test for Alzheimer’s disease.
Rather, it takes a consultation between physicians and neurologists utilizing different
approaches and methods to reach a diagnosis. The patients’ medical and family history
should be examined, as well as their psychiatric history and a history of cognitive and
behavioral changes. Medical personnel should confer with family members or individuals
close to the patient, to provide input on changes in thinking skills or behavior. Cognitive
tests along with physical and neurological examinations may be conducted as well. In
order to affirm the diagnosis, the patient may undergo blood tests and brain imaging.
Testing can rule out other potential causes of dementia symptoms, such as a tumor or
particular vitamin deficiencies. Diagnosing Alzheimer’s disease requires a careful and
comprehensive medical evaluation. Although physicians can almost always determine if a
person has dementia, identifying the exact cause may pose some difficulty. Several days
or weeks may be needed for the patient to complete the required tests and examinations
and for the physician to interpret the results and make a diagnosis [6].
AD pathology is characterized by three distinct hallmarks: Extracellular amyloid
(senile) plaques with amyloid beta (Aβ) protein being the main component, intracellular
neurofibrillary tangles comprised of hyperphosphorylated tau protein, and noticeable
neuronal loss [7].
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The pace of the disease, how fast it progresses, differs from one patient to another,
much like the symptoms. While all patients experience similar symptoms, there are two
well-established types of AD.

The first type is early-onset AD (EOAD) which is

associated with progressive deposition of Aβ peptides in patients < 60 years of age, and it
accounts for 1-5% of all AD cases [4, 8-11]. The second type is late-onset AD, which
accounts for ≥ 95% of cases. Despite sharing the same pathophysiology, the etiology of
EAOD and LOAD are different. While EOAD is mainly genetic, LOAD is more complex
and multifactorial with several risk factors participating in the development of the disease,
including genetic and environmental risk factors and most importantly aging [8].
The pathogenic Aβ is the product of proteolytic cleavage of Amyloid precursor
protein (APP) [12]. APP is an integral membrane glycoprotein that is expressed in several
tissues. The exact physiological role of APP is not clear, however, in the brain it is reported
to contribute to neurite outgrowth, synaptic plasticity, and regulation of neuronal
excitation. APP can be produced as several isoforms with a size ranging from 695 to 770
amino acids [13]. APP695 represents the most abundant form of APP in the brain and it is
produced mainly in neurons. The three enzymes responsible for cleavage of APP are alpha,
beta and y-secretase. This process can happen in two ways: amyloidogenic or nonamyloidogenic. Under normal non-amyloidogenic conditions (approximately 90% of APP
cleavage) α-secretase first cleaves APP within the Aβ-region releasing APPα from the cell
surface and an 83-amino acid C-terminal fragment (CTF)–α. CTF- α is further cleaved by
γ-secretase into P3(3 KDa) and APP intracellular domain(AICD)[13, 14]. By contrast, the
remaining 10% of APP is cleaved by amyloidogenic processing, which involves sequential
cleavage of APP by β-secretase followed by γ-secretase. β-secretase cleavage results in
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the formation of soluble APPβ and CTFβ, which is further processed by γ-secretase.
Unlike the β-secretase processing site, which is precisely at amino acid 671 of APP, γsecretase cleavage is rather imprecise and could happen in multiple sites producing
fragments of 43, 45, 46, 48, 49 and 51 amino acids. These fragments are further cleaved
in endocytic compartments into 40 and 42- amino acid Aβ (Aβ40 and Aβ42), the two main
forms of Aβ[15]. (Fig.1.1).
The pathogenesis of AD is often attributed to the dynamics of production and
clearance of Aβ, especially Aβ42. Hence, amyloid positron-emission tomography (PET)
imagining as well as decreased levels of Aβ42 and/or Aβ42/Aβ40 ratio in cerebrospinal
fluid (CSF) are recommended for diagnosis of AD [16].
On the other hand, neurofibrillary tangles (NFTs) are intraneuronal cytoplasmic
bundles of paired, helically wound filaments comprised of hyperphosphorylated tau
protein [17]. Under physiological conditions, tau modulates the stability of axonal
microtubules [18]. Tau contains 85 phosphorylation sites and therefore it is not surprising
that phosphorylation, at any of these sites, profoundly impacts its function. Under
pathological conditions such as AD, tau becomes hyperphosphorylated, reducing its
affinity for microtubules and destabilizing the cytoskeleton of the affected neuron [18].
Additionally, hyperphosphorylation of tau promotes aberrant assembly of tau into
insoluble aggregates that induce synaptic dysfunction and neuronal cell death.

4

1.1.2

The Amyloid Cascade (amyloid beta) Hypothesis

In 1984, George Glenner was the first to propose that a particular amyloidogenic
protein accumulates in AD and could be the causative of the disease pathology[19].
However, it was in 1991 (Beyreuther & Masters; Hardy & Allsop;Selkoe) when the
amyloid hypothesis idea was put forward and to this day remains the dominant model of
AD pathogenesis[20-22]. The hypothesis proposes that the production and excessive
accumulation of Aβ, both intracellularly and extracellularly, under different aggregation
and physical states, instigate a pathological progression cascade leading to neurofibrillary
tangles formation, synaptotoxicity, mitochondrial dysfunction, chronic neuroinflammation
arising from aberrant activation of glial cells, and ultimately neurodegeneration and
dementia. Despite the lack of consensus about this hypothesis, it remains one of the most
extensively validated and compelling hypothesis of AD pathogenesis[23, 24].
Several lines of evidence support the Aβ hypothesis, most notably was the
discovery that humans with trisomy 21 (Down’s syndrome) harbor 3 copies of APP and
experience an increased risk for developing neuropathologically typical AD as they
age[25]. In fact, almost all Down syndrome adults over the age of 40 exhibit
neuropathology sufficient for an AD diagnosis. The APP gene is located on chromosome
21, indicating that Down’s syndrome patients develop typical Alzheimer neuropathology
due to the over production of Aβ throughout their lives. Interestingly, patients with partial
trisomy 21, with translocation involving only the distal part of chromosome 21 telomeric
to the APP gene, develop Down Syndrome features but not AD. On the other hand,
individuals presenting micro-duplicated APP gene but not the whole chromosome 21
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develop EOAD but do not get Down syndrome, directly implicating overexpression of
APP as a cause of Aβ deposition in adult life [26].
Significant support for the Aβ hypothesis comes from the genetic mutations
related to EOAD. Mutations in APP that happen within the Aβ sequence lead to the
production of peptides that are characterized by high self-aggregation ability. Moreover,
mutations in the genes encoding for active sites of the APP processing enzyme γ-secretase,
presenilin 1 (PSEN1) or presenilin2 (PSEN2), alter the proteolytic cleavage of APP,
resulting in overproduction of Aβ42 or Aβ43 peptides. These mutations are estimated to
be responsible of 71% of EAOD cases, however, that means they explain roughly 0.5
percent of all AD cases given that EAOD accounts for only 1-5% of total AD cases [27,
28]. Astonishingly, inheritance of a missense APP mutation (A673T) located at the second
amino acid of the Aβ region results in constant reduction of APP cleavage by β-secretase
[29, 30]. Carriers of this mutation show no sign of Amyloid plaques up to 100 years of
age, and they have a lower risk of developing clinical AD.
Apolipoprotein E (ApoE) is a lipid-transporter protein involved in the transport and
metabolism of cholesterol and other lipids and is immunochemically colocalized with
amyloid plaques, neurofibrillary tangles, and vascular amyloid deposits in AD [31]. Due
to several single-nucleotide polymorphisms (SNPs), ApoE is found in three isoforms, ε2
(cys112, cys158), ε3 (cys112, arg158), and ε4 (arg112, arg158) with frequencies of 8.4%,
77.9%, and 13.7%, respectively. Despite being the most frequent allele, ε3 is believed to
play no significant role in AD, while ε2 is known to be protective and ε4 is shown to be
the strongest genetic risk factor in LOAD [31]. Frequency analysis of the three alleles
among human populations exhibited robust association between ε4 allele and LOAD with
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approximately 40% frequency of the ε4 allele. In a double transgenic mouse model of APP
and hApoE, the clearance of Aβ is shown to be decreased by ApoE4 > E3 > E2 in a degree
closely related to Aβ deposition in the brain [32]. Therefore, whether it is EOAD or LOAD,
genetic risk factors support the amyloid hypothesis, either by promoting the amyloidogenic
processing of APP or by disruption to Aβ clearance mechanisms.
While the original amyloid hypotheses (cascade hypothesis) focused more on the
senile plaques with respect to their potential toxicity and drug development, the field has
shifted towards oligomeric amyloid beta(oAβ) as being the culprit initiating brain damage
prior to AD progression. This notion was supported by the clinical observations that
amyloid plaque load does not necessarily correlate with the cognitive status of the patients
[33]. On the other hand, highly demented individuals carrying a distinct APP mutation,
namely the Osaka mutation of APP E693, manifested higher levels of oAβ and other
aspects of AD pathology without developing plaques [34-36].
Additionally, several studies showed that soluble oAβ, isolated for human AD
brains, led to impairment in synaptic plasticity in the entorhinal cortex and neocortex
when injected into the brains of healthy rats[37]. Moreover, human oAβ can trigger tau
hyperphosphorylation in primary cultured rat neurons[38].
Considering how intricate AD pathogenesis is, oAβ has been implicated into a
rather complex cellular system comprising continuous feedforward and feedback
responses between neurons, glial cells, and vasculature. For example, oAβ has been shown
to induce reactive oxygen species (ROS) in astrocytes leading to astrogliosis [39, 40]. oAβ
has also been found to increase intracellular Ca++ levels in astrocytes within minutes of
exposure [40]. Lastly, exposure of both neuron and astrocytes to oAβ leads to activation
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of Ca++-sensing receptors, triggering both cell types to secrete nitric oxide (NO), and
vascular endothelial growth factor A (VEGF-A), and Aβ42[41]. Astrocytic Aβ has been
shown to be secreted encapsulated into extracellular vesicles (like exosomes), possibly
contributing to the demise of neurons.

1.1.3

Amyloid beta toxicity in Alzheimer’s Disease

As mentioned earlier, Aβ42, in particular oAβ, is widely perceived as the most toxic
factor in AD pathogenesis. A well-defined mechanism by which Aβ exerts its toxic effects
is not yet clear, however, several groups have proposed potential mechanisms.
One heavily studied mechanism is the effect of Aβ on neuronal synaptic plasticity
[42-45]. Synaptic plasticity is an activity-dependent biological process in which neurons
brings about changes in the strength and efficacy of synaptic transmission at preexisting
synapses, and it is known to play a crucial role in memory and learning [46]. There are
two major forms of synaptic plasticity: Long-term potentiation (LTP) which enforces the
synaptic transmission, and long-term depression (LTD) which leads to reduction in
synaptic function and transmission. α-amino-3-hydroxy5-methyl-isoxazole-4-propinonic
acid receptors (AMPARs) and NMDA receptors (NMDARs) are two major ionotropic
glutamate receptors that are involved in regulation of synaptic transmission. Regulation of
LTP and LTD by both NMDARs and AMPARs involves endocytosis and trafficking of
these receptors, that is, when stimulation of NMDR leads to post-synaptic increase in Ca2+
followed by signaling events ending in re-colocalization of new AMPARs to the plasma
membrane[47, 48]. In part, Aβ causes synaptic dysfunction by disrupting glutamate levels
through aberrant stimulation of NMDARs, which in turn results in desensitization of
8

NMDARs preventing the induction of LTP. In addition, high levels of Aβ have been
associated with increased internalization of AMPAR, which promotes LTD [49-51].
Partial antagonists to NMDARs mitigate the Aβ-induced overstimulation to the receptors
in primary neurons of mice and rats. This concept describes the possible mechanism of
action of memantine, which is clinically prescribed for AD patients [52, 53]. Moreover,
Aβ interacts with the cholinergic receptor α7 nAChR, and promotes NMDA receptors
endocytosis and subsequently disrupts cholinergic neurotransmission [54-57].
Aβ has been shown to interact with other receptors as well. Such receptors include
Ryanodine receptors, which are calcium-release channels, known to be localized in the
soma, spines and proximal dendrites of neurons. Exposure to Aβ leads to enhanced
expression and activity of ryanodine receptor 3 and ultimately intracellular Ca 2+
homeostasis disruption [58, 59].
The chemical characteristics of Aβ prompts it to directly interact with lipid
membranes in aqueous environments, allowing for interaction with lipids, phospholipids,
and membrane-bound proteins[60]. Several groups have reported that Aβ is able to selfassemble within lipid bilayers, creating pore-like hollow structures of annular Aβ
oligomers with a hydrophilic interior and hydrophobic exterior[61-64]. This could be due
the detergent-like properties of Aβ, allowing it remove lipid molecules and destabilize
membranes. Later, this pore-like morphology was confirmed using high-resolution atomic
force microscopy and has been found in postmortem brain tissues of AD patients as
well[61]. It has been proposed that these Aβ pores work as Ca2++ -sensitive ion channel,
which might explain the Ca2++ influx in neurons leading to Ca2++ dyshomeostasis [64].
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This in turn might trigger mitochondrial dysfunction instigating a cascade of ROS and
subsequently apoptosis[65, 66].
Aβ toxicity has also been traced to intracellular organelles either directly after
internalization or as a consequence of initial cell surface interaction, one of these
organelles are mitochondria[67-69]. In fact, a decrease in glucose metabolism was
observed in areas associated with amyloid plaques, implicating Aβ in the process[70]. In
addition, mitochondrial dysfunction was observed prior to the amyloid plaque
deposition[71, 72].
As mentioned earlier, Aβ can penetrate lipid membranes, including mitochondrial
membranes, and has been reported to disrupt the electron transport chains [73-76]. Aβ
decreases the activity of the terminal enzyme in the electron transport chain cytochrome
C, by interfering with its binding to cytochrome c oxidase [67, 77-80]. Another enzyme
that is shown to be affected by Aβ is amyloid-binding alcohol dehydrogenase (ABAD),
which is a multifunctional mitochondrial enzyme involved in energy production and is
upregulated in AD [81, 82]. ABAD undergoes conformational changes when bound to Aβ,
which prevents the enzyme from binding to NAD+, resulting in the loss of ABAD
enzymatic activity [81].
Another form of the deleterious effect of Aβ on mitochondria is the direct
dysregulation of mitochondrial fission and fusion [83, 84]. As the terms suggest,
mitochondrial fusion means combining two mitochondria into one, while fission means
dividing one into two [85, 86]. Fusion and fission are controlled dynamic processes that
occur at a high frequency in response to cellular and mitochondrial conditions.
Dysregulation of fission and fusion leads to either elongated misshapen mitochondria
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(excessive fusion) or mitochondrial fragmentation (disproportionate fission). One key
regulator of mitochondrial fission is the dynamin-like GTPase protein dynamin-related
protein 1 (DRP1) [87-89]. It has been shown that Aβ activates DRP1 through Snitrosylation causing mitochondrial fragmentation and synaptic degeneration in AD [90].
Voltage-dependent anion channel 1 (VDAC1) also interacts with Aβ monomers
and oligomers[91-93], and the block of those mitochondrial pores leads to mitochondrial
dysfunction. VDAC1 is a mitochondrial gatekeeper located on the outer mitochondrial
membrane that regulates the metabolic cross-talk between mitochondria and the rest of the
cell[94, 95]. VDAC1 regulates the entry of metabolites into the mitochondria including
malate, nucleotide, succinate, and NADH while allowing the release of hemes and other
molecules outside of mitochondria. Under normal physiological conditions, VDAC1 is
found in a dynamic equilibrium between monomeric and dimeric states. However, when
VDAC1 is subjected to an insult, it assembles into a higher oligomeric structure, forming
a channel. Those channels allow the passage of cytochrome C to the cytosol, ultimately
leading to apoptosis[96-98].
Recent evidence has implicated the VDAC1 in AD pathogenesis, evident by the
demonstration that interactions between VDAC1, Aβ, and phosphorylated tau were shown
to lead to mitochondrial dysfunction[99, 100]. In addition, Hippocampal extracts of AD
transgenic mice showed increased levels of VDAC1 in the outer mitochondrial
membranes. Higher expression levels of VDAC1 were demonstrated in the dystrophic
neurites with Aβ deposits in the brains of both AβPP transgenic mice and AD post-mortem
individuals, as well[101]. Lastly, soluble oligomeric Aβ is reported to cause apoptosis in
neurons as a result of upregulation and oligomerization of VDAC1[102].

11

1.2

Extracellular vesicles
1.2.1 History and Background

The phenomenon of cellular secretion of small vesicles was first reported in the late
1960s, when Bonucci and Anderson noticed that chondrocytes secrete nanosized vesicles
of ∼100 nm[103, 104]. During the same time period, another group showed that platelets
secrete small vesicles as well, which they referred to as platelet dust[105]. These

extracellular vesicles (EVs) were overlooked for two decades, but were then discovered to
harbor cell specific proteins, genetic material and lipids that are delivered to other cells
where they could alter diverse functions[106-109].
The first reported functional role of EVs came from the field of immunology. B
lymphocytes secreted EVs and demonstrated a transfer of antigens, major
histocompatibility peptide complexes that are recognized by T lymphocytes, suggesting a
role of EVs in immune response induction[110]. Two years later, the same group
demonstrated that dendritic cells secrete EVs bearing functional peptide complexes as well,
which can trigger antitumor immune responses in mice, in vivo [111]. These results
provided the groundwork for the popular concept that EVs could play an active role in
intercellular communication, at least in the immune system. This hypothesis proved to hold
true in several other systems as well. Another breakthrough took place in 2007 when Jan
Lötvall and group members described the presence of microRNA (miRNA) inside these
vesicles, leading to a surge in the number of studies and publications in the pursuing
years[112].
The term “exosomes’ describes the intra luminal vesicles (ILVs) that originate in
the multivesicular bodies (MVBs). This terminology is widely accepted; however, the word
“exosomes” was not actually implemented until 1987[113]. Microvesicles are another
well-studied, secreted vesicle[114, 115]. One notable difference between the two types of
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EVs is the size. While exosomes, or small extra cellular vesicles, have a size range of ~40
to 160 nm (with an average of ~100 nm) in diameter, the size of microvesicles usually is
in the range of ~150-1000nm in diameter[116, 117]. This difference allows for the
separation of the two types of vesicles via differential ultracentrifugation. In most cases,
larger vesicles preferentially sediment at a relatively low g force (e.g., 30 min at 10,000 ×
g), while smaller vesicles need a higher g force (e.g., 90–120 min at 70,000–120,000 × g)
to sediment.
Another apparent difference between exosomes and microvesicles is that exosomes
are specifically enriched with certain types of cell-specific proteins, lipids, and nucleic
acids[118]. On the other hand, microvesicles are a smaller representation of the cells of
origin, in terms of composition. Granted, there are other types of microvesicles reported in
literature, such as apoptotic bodies and ectosomes, which are derived from cells undergoing
apoptosis and plasma membrane shedding, respectively[119, 120]. Although apoptotic
bodies, ectosomes and exosomes roughly share same size (typically 40–100 nm) they are
essentially different species of vesicles.
1.2.2

Biogenesis

Exosomes are typically formed through a process that involves double invagination
of the plasma membrane leading to the formation of multivesicular bodies (MVBs) that
contain intraluminal vesicles (ILVs)[113]. This process was first observed during studies
concerning elimination of transferrin receptor (TfR) from the plasma membrane of
maturing reticulocytes[121]. The process of MVB biogenesis was shown to involve
selective endocytosis of TfR from the plasma membrane, followed by budding of TfR from
the endosomes’ membrane into the endosomal lumen, and then fusion of the MVBs with
the plasma membrane. There are several routes that MVBs could take. While some MVBs
fuse to the plasma membrane to release there ILVs (exosomes) into the extracellular milieu,
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others fuse with lysosomes or autophagosomes for degradations, or contribute to
specialized organelles generation such as Weibel-Palade bodies (endothelial cells),
secretory granules (in mast cells), and melanosomes (in melanocytes)[122]. It is thought
that the cholesterol level within MVBs plays a role it their fate, while cholesterol-rich
MVBs are directed to the plasma membrane, alternatively, the cholesterol-poor MVBs
favor the lysosome fusion fate[123].
In general, MVB biogenesis is driven by either endosomal sorting complexes
required for transport machinery (ESCRT)-dependent and or ESCRT-independent
pathways (Fig. 1.2)[124]. The ESCRT machinery consists of a distinct group of cytosolic
protein complexes (ESCRT-0, -I, -II and -III). These complexes orchestrate the ILVs
generation in a stepwise fashion. They are recruited to endosomes through interaction of
ESCRT-0 and ESCRT-I with tagged, usually ubiquitylated, transmembrane proteins from
microdomains in the endosomal membrane followed by recruitment of ESCRT- III.
ESCRT-II is the last complex to engage in this process, and it is believed to be responsible
for vesicles detachment and release.
The ESCRT machinery participates in exosome biogenesis through other
mechanisms as well, one of which involves the syndecan-syntenin-ALIX axis as recently
described by Baietti et al[125]. They report that the syndecan heparan sulphate
proteoglycans, with the help of their cytoplasmic adaptor syntenin, regulate endosomal
biogenesis of exosomes. ALIX protein is known to be functionally important for the
ESCRT machinery through interacting with several ESCRT proteins, like TSG101 and
CHMP4. In their study, Baietti et al. showed that Syntenin binds directly to ALIX and
triggers the intraluminal abscission of endosomal membranes.
Several lines of evidence indicate an overlap between the autophagy pathway and
exosome biogenesis and secretion[126-128]. This was predictable due to the verity that
autophagy is a lysosomal-dependent degradation and recycling pathway, and it is plausible
that autophagy shares some molecular machinery with exosomes biogenesis. In fact, it has
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been recently shown that autophagy pathways secrete waste in endosomal-derived vesicles,
resembling the exosome biogenesis process. Many proteins have been identified as key
players in both autophagy and exosome production. A recent study by Gudbergsson and
Johnsen compared a list of proteins involved in several autophagy pathways to that of EV
protein database named Vesiclepedia[129]. The authors reported that nearly all autophagy
key proteins have been identified in EV literature[130]. Noticeably, four of the autophagyrelated proteins were HSPA8, HSP90AA1, VCP, and Rab7A all of which are well
recognized proteins in EV production processes.
Another shared protein between autophagy and exosome biogenesis is the class III
PI3K complex. This complex includes proteins such as Beclin-1, p150, VPS34, and other
accessory proteins. PI3k exerts its regulatory role through the generation of PI (3)P via
phosphatidyl inositide phosphorylation[131]. With the help of other proteins, namely
ATG14L and UVRAG, PI (3)P regulates autophagosome maturation and endosome
development, respectively[132].
The extensive mention of MVBs as the origin of exosomes in literature does not
necessarily mean that endosomal budding is the only method for the generation of
exosomes. Stephen J. Gould and others have shown in several reports that exosomes can
be formed through direct budding from the plasma membrane[133-135]. Unfortunately,
these are largely ignored by most models of exosome biogenesis, which conveys an
endosome-only view of exosome biogenesis. This relatively new mechanism has been
observed using techniques such as atomic force microscopy, electron microscopy, and
cryo-electron microscopy. In addition, recent studies show the presence of deep
invagination in the plasma membrane, that resembles MVBs, when using conventional
transmission electron microscopy. These invaginations are called intracellular plasma
membrane–connected compartments (IPMCs) and are shown to be continuous with the
extracellular space through necks, allowing free passage of small-molecules and
extracellular buffer while preventing the escape of vesicles. This process might explain the
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enrichment of integral membrane proteins or proteins within lipid rafts of the plasma
membrane and in the newly formed exosomes.
1.2.3

Sphingolipids in Extracellular vesicle

In ESCRT-independent manner, two enzymes involved in lipid metabolism have
been shown to drive the formation of ILVs in in the lumen of MVBs. Phospholipase
D2(PLD2) hydrolyzes phosphatidylcholine into phosphatidic acid (PA) at the inner leaflet
of late endosome membranes[136]. The negative charge of PA drives the inward budding
of ILVs inside MVBs. The second enzyme involved in ESCRT-independent exosomes
biogenesis

is

neutral

sphingomyelinase

2(nSMase2)[137].

nSMase2

hydrolyze

sphingomyelin to produce ceramide[138], a cone-shaped sphingolipid that triggers
spontaneous curvature of membranes leading to invagination and budding of exosomes
into the late endosomes (MVBs).
Sphingolipids constitute a major component of membranes in eukaryotic
cells[139]. The first sphingolipids were isolated from the brain in the late 19th century by
Thudichum[140]. He then coined the term “sphingosin” after the Greek mythical creature,
Sphinx, as they presented as enigmatic molecules. Sphingolipids are a very complex and
diverse group of lipids comprised of hundreds of lipids[141-143]. In addition to being a
part of cell membrane, sphingolipids are shown to be involved in the formation of
structures called” lipid rafts”, roughly 50-200nm diameter microdomains that are enriched
with certain sphingolipids and incorporate proteins, named raft-associated proteins
(RAPs)[144-146]. The presence of RAPs within the lipid rafts implicates these
microdomains in cell signaling integration. Ceramide is the core constituent of all complex
sphingolipids and its structure consists of a sphingosine long-chain backbone linked to a
fatty acid via an amide linkage[139, 147].
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In addition to exosome biogenesis, ceramide is a key player in various aspects
of cellular processes including growth, survival, senescence, proliferation, and apoptosis.
This functionality of ceramide qualifies it as a biologically active cell signaling lipid, along
with other sphingolipids such as sphingosine 1 phosphate(S1P) and sphingosine [145].
Ceramide synthesis can occur via two distinct pathways; the anabolic (also known
as de novo) and the catabolic (frequently referred to as salvage) pathways [148, 149] (Fig.
1.3). The de novo pathway is initiated by the condensation of serine and palmitoyl-CoA to
produce 3-ketodihydrosphinganine, catalyzed by the enzyme serine palmitoyl transferase
(SPT). 3-ketodihydrosphinganine is then reduced to sphinganine (Dihydrosphingosine)
through the enzymatic action of enzyme 3-ketodihydrosphingosine reductase. Sphinganine
is N-acylated to dihydroceramides (DHCer) by ceramide synthases (CerS), a family of
acyl-CoA transferases that controls the fatty acyl chain length. There are six established
CerSs in mammalian cells, with CerS1 being the most abundant one in the brain(neurons),
specifically attaching C18 fatty acyl CoA to the sphingoid base. Finally, ceramide
formation is completed by the enzyme dihydroceramide desaturase through desaturation of
the of DHCer, which introduces a 4,5-trans double bond at the sphinganine base of
DHCer[138, 139].
On the other hand, the salvage pathway re-utilizes long chain sphingoid bases,
mostly from sphingomyelin, to produce ceramide. Sphingomyelin represents the most
abundant sphingolipid in cell membranes, subsequently playing a vital role in membrane
fluidity and homeostasis. Sphingomyelin is a substrate for a family of enzymes called
sphingomyelinases (SMases) which hydrolyze sphingomyelin into ceramide and
phosphocholine. Five SMases have been identified in literature and they can be generally
separated in to two groups, namely acid and neutral SMases, depending on their subcellular
localization, pH optima, and cation requirements for enzymatic activity. It has been
speculated that nSMase2, the brain specific form of SMases, is present in an inactive form
under normal conditions. Upon stimulation with different extracellular factors and
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intracellular processes, including tumor necrosis factor α (TNF-α), interleukin 1β/6, and
oxidative stress, nSMase2 then moves to the plasma membrane where it facilitates
ceramide production and the downstream effects[150]. In addition, nSMase2 has been
shown to partake in pro-inflammatory cytokine signaling, implicating the enzyme in the
progression of several neurodegenerative diseases[151, 152].
In general, alteration in ceramide (and other sphingolipids) levels or metabolism
has been linked to numerous neurodegenerative diseases including epilepsy, Parkinson’s
disease, Huntington’s disease, Gaucher’s disease, Krabbe’s disease, and AD[153-158].
Ceramide has been proven to have a multifaceted role in neurodegenerative diseases,
especially AD. Due to advances in mass spectrometric methods, researchers were able to
show that ceramide levels are elevated in the serum, cerebrospinal fluid (CSF), and brains
tissues of AD patients[159-162]. In addition, plasma ceramide levels have been shown to
directly correlate with brain hippocampal volume in late onset AD patients.
As a part of The Women’s Health and Aging Study ∥, Mielke and colleagues

followed 99 cognitively normal older women for nine years in a prospective cohort study.
They were able to show concrete relationship between higher baseline serum ceramide
levels and the risk of developing dementia and AD, priming serum ceramide as a biomarker
for preclinical AD. More specifically, researchers were able to narrow down certain
ceramide species that are elevated in aging and AD, such as Cer16, Cer18, Cer20, Cer24,
and Cer24:1[161].
On a cellular level, endogenous ceramide within lipid rafts in the plasma
membrane, as well as the ceramide analog C6-ceramide, were shown to directly increase
the production of Aβ by stabilizing the β-site APP cleaving enzymes[163]. Moreover,
exposure to Aβ activates nSMase 2 in vitro, which might be associated with facilitating Aβ
aggregation and spreading given the role of nSMase 2/ceramide in exosomes
production[164].
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Concomitantly, Aβ can indirectly increase the production of ceramide through an
oxidative stress-mediated mechanism[165, 166]. Exosomes formed through the nSMase 2
pathway are being packaged with misfolded proteins, which might provide an efficient way
for cellular uptake during different neurodegenerative diseases[167]. In fact, oligomeric αsynuclein displayed higher levels of cellular uptake when associated with exosomes rather
than its free form[168].
It is worth mentioning that all the previous reports pertaining the interplay
between ceramide and Aβ have been conducted in neuronal cells. Recently, the same
concept has been gathering interest in glial cell. First, ceramide has been shown to sensitize
astrocytes to oxidative stress[169]. Human post-mortem tissues of frontotemporal lobar
dementia (FTLD) demonstrated increased levels of ceramide in astrocytes as well, which
correlated with the level of neuroinflammation[170]. In addition, treating primary
astrocytes with oligomeric Aβ led to the release of ceramide enriched exosomes that cause
apoptosis to recipient astrocytes[164].
The presence of ceramide in several cellular membranes leads to the discovery of
its role as a regulator of organelle functions and cellular transport. This role involves
regulation of membrane curvature, fission and fusion, endocytosis, cellular transport,
vesicular transport, as well as mitochondrial function[171-175]. Ceramide regulation of
mitochondrial function is multifaceted, it could assist in protein transfer, interact with
mitochondrial membrane proteins, or directly interact with the membrane lipid
bilayer[176-179]. Excess ceramide that dysregulates mitochondrial function may originate
from the upregulation of endogenous ceramide generation, from the endoplasmic
reticulum, other organelles or the uptake of ceramide contained within “mobile lipid rafts”
in exosomes. Ceramide has been reported to increase the mitochondrial outer membrane
permeability through interactions with several kinases and phosphatases that govern the
apoptosis process. For instance, elevated ceramide levels inhibit phosphoinositide-3-kinase
(PI3K) and Akt/PBK signaling, which results in the activation of pro-apoptotic Bcl-219

family protein Bad[180]. In addition, coarse-grain molecular dynamics simulations showed
that VDAC1 carries a ceramide binding site, directly implicating ceramide in
mitochondrial apoptosis[181]. In model bilayers and isolated mitochondrial outer
membranes, ceramide was found to form pores large enough to that allows the passage of
cytochrome c[182].

1.2.4

Exosomes in AD

Exosomes were first implicated in AD as carriers of pathogenic proteins and
causative of impaired neuronal function[183, 184]. Firstly, Aβ peptides were shown to
accumulate in MVBs using electron microscopy on AD transgenic mouse models as well
as human AD brain sections[185]. This was followed up a study showing colocalization
between flotillin-1, the raft and exosomal marker, with Aβ in the lumen of MVBs.
In 2006, Rajendran and colleagues were first to show that β-cleavage of APP
occurs in early endosomes[186]. That is followed by routing Aβ to MVBs in N2a and Hela
cells. The same study estimated that a minute fraction of Aβ (<1%) is then secreted from
cells to the extracellular space in association with exosomes. They also found that the
ESCRT accessory protein Alix to accumulate in the plaques of AD patient brains,
suggesting a role of exosomes in Aβ aggregation and plaque formation. Further evidence
for the role of MVBs in APP metabolism came from the study on SY5Y neuroblastoma
cells. Upon treatment of SY5Y cells with alkalizing drugs like chloroquine or bafilomycin
A1, APP CTFs and amyloid intracellular domain (AICD) accumulate in MVBs prior to
their secretion within exosomes[187]. Recently, the packaging of APP into exosomes has
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been shown to be regulated by vesicle-associated proteins Alix and Syntenin-1[188].
Furthermore, APP-processing enzymes (β-secretase and γ-secretase components PS1 and
presenilin-2) were shown to be secreted in exosomes, using Chinese hamster ovary (CHO)
cells[189]. Same exosomes contained APP-CTFs and Aβ. More recently, a group in
Sweden showed that intact exosomes and their cargo, including human AD brain oAβ, can
be transferred from one neuron to another using a co-culture method that utilizes two
different neuronal cell types[190]. The authors provided evidence that exosome uptake
into neurons is an active process (dynamin dependent) and preincubation of cells with the
endocytosis inhibitor dynasore leads to significant reduction in oAβ uptake, propagation,
and subsequent toxicity. The previous studies not only implicate exosomes in spreading of
Aβ, but also in facilitating APP cleavage into Aβ in the recipient neurons.
Tau, on the other hand, is known to spread in AD brain in a well-defined manner,
from one region to another, with the uptake of pathological tau causing misfolded
aggregations of monomeric tau in recipient cells[191-193]. This “prion like mechanism”
of spreading led scientists to propose a role of exosomes in the propagation of tau. Indeed,
tau phosphorylated at Thr-181(AT270) was found associated with exosomes in human
CSF as well as M1C neuroblastoma cell cultures[194]. Notably, exosome-associated tau
(relative to free tau) is elevated in CSF during mild AD, suggesting a role of exosomal tau
secretion in the abnormal processing of tau, preceding cell death at later stages. The same
authors took this study further by demonstrating that overexpression of human tau in
neuroblastoma cells leads to recruiting mitochondrial proteins that are involved in
axonogenesis relevant to neurodegeneration into the exosomal secretion pathway[195]. In
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another overexpression study, tau was found to be secreted in association with membrane
vesicles after reaching a threshold intracellular concentration level[196, 197].
Asai and colleagues generated the most compelling study by demonstrating the role
of exosomes in tau propagation[198]. Their in vivo study was the first to display the rather
surprising role of microglial exosomes as tau spreads. Using two separate mouse models,
the authors were able to show that microglia phagocytose tau was followed by exocytosis
in association with exosomes. They continued to demonstrate that depletion of microglia
through either i.c.v. infused clodronate liposomes or feeding the mice an inhibitor of
colony stimulating factor 1 receptor (CSF1R) resulted in significant reduction in tau
propagation. They also showed that inhibition of exosome synthesis significantly reduced
tau propagation in vitro and in vivo. The implication of microglial EVs in spreading of
toxic pathogens is further supported by a study showing that treating primary microglia
with Aβ leads to the production of Aβ-containing macrovesicles that are neurotoxic in
vitro [199]. Recently, one study linked Bridging Integrator 1 (BIN1), a major locus
associated with LOAD, to the secretion of tau in exosomes [200]. It was reported that
overexpression of BIN1 triggered the release of tau-associated exosomes and genetic
deletion of the gene from microglia significantly reduced tau spreading in vivo.
Apart from being a carrier for several pathogens involved in AD and other
neurodegenerative diseases, exosomes have also been shown to have neurotoxic effects
relative to AD pathology. For instance, primary astrocytes treated with Aβ were shown to
secrete exosomes that carry Aβ, enriched with ceramide, and harbor the pro-apoptosis
prostate apoptosis response-4(PAR-4)[164]. These exosomes proved to induce apoptosis
in recipient astrocytes. More recently, Ikezu’s group reported that activated human
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astrocytes (treated with interleukin-1β) secrete exosomes with higher level of enrichment
of integrins and major histocompatibility complex[201]. These exosomes lead to neurite
fragmentation accompanied by a reduction in neuronal branching and firing, when they
were added to primary cultured mouse cortical neurons. On subcellular level, exosomes
from the CSF of late-onset AD or PS1 mutation-harboring cells were shown to impair
Ca2+ handling and mitochondrial function in cultured neurons[202].
Despite the plethora of articles attributing toxic effect to exosomes, other
beneficial roles of exosomes have also been reported. The initial reports pertaining to the
advantageous role of exosomes in AD came in a series of publications from Yuyama and
colleagues, describing an exosome dependent Aβ clearance[203]. The authors utilized a
transwell co-culture system of human APP-transfected N2a cells and microglial BV2 cells
to show that microglia engulf neuronal exosomes containing Aβ, which participates in the
clearance of the peptide and reducing its pathology. They followed up with an in vivo study
two years later where they continuously infused neuronal exosomes intracranially into
transgenic AD mouse brains for two weeks using osmotic pumps[204]. They were able to
demonstrate that exosomes injections decreased the levels of Aβ and ameliorated its
toxicity with respect to synaptic density reduction in hippocampus of four month-old mice.
They reported similar findings in 12 months old transgenic mice, as well. Of note, the
exosomes used in these studies came from normal wild type neurons or neuroblastoma cell
lines and the exact mechanism of the protective role of these exosomes remains elusive.
Another example of the beneficial role of exosomes in AD came from a separate in vivo
study using Intracerebroventricularly (i.c.v) infusion of N2a cells or human cerebrospinal
fluid derived exosomes. These exosomes were shown to abrogate the synaptotoxic effects
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(disruption of long-term potentiation) of both synthetic and AD brain-derived Aβ. In this
study, Aβ peptides were shown to be sequestered by exosomes with the help of exosomal
surface proteins including cellular prion protein (PrPC)[205]. Additionally, human
umbilical cord mesenchymal stem cells (huc-MSC)-derived exosomes proved to exhibit
preventive

effects

when

injected

into

double

transgenic

mouse

model

of

AD(APP/PS1)[206]. These exosomes helped abrogating neuroinflammation through
altering the levels of expression of pro- and anti-inflammatory cytokines. The effect of
these exosomes extended to enhance spatial learning and memory function in addition to
reducing the amyloid plaques load in the cortex and hippocampus on the injected animals.

Since exosomes are capable of carrying proteins as cargo, it is not surprising that
several groups reported the presence of Aβ degrading enzymes in exosomes, representing
another potential protective role of exosomes in AD[207-210]. Some of the enzymes
reported were found in the last-mentioned study since the authors reported upregulated
levels of insulin-degrading enzyme (IDE) and neprilysin in the exosomes. Others reported
the presence of metalloproteinases and endothelin-converting enzymes, both have Aβdegrading capabilities, in association with exosomes.
Being biological entities, exosomes are known to freely cross the blood brain
barrier (BBB) in both directions[211-213]. This unique capability posed exosomes as an
exciting drug delivery method. In addition, the presence of exosomes in peripheral
circulation allowed researchers to capture them, away from the brain, and study their
content and cargo aiming to find unique exosomal biomarkers relative to
neurodegenerative diseases, making them a potential diagnostic tool.
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Exosomes contain constituents of their cells of origin, which turns them into
biomarkers for the secreting cells. Utilizing this concept, efforts have been made to enrich
for exosomes from distinct brain cells, especially neurons and astrocytes. In the context of
AD, it does not come to surprise that the first thought after targets were the major culprits
in AD pathophysiology, namely Aβ, tau, and p-tau. Precisely the Aβ1-42/1-40 ratio, T tau and p -tau are being already used as biomarkers in CSF-based neurochemical diagnosis,
and the same molecules have been identified in serum exosomes[214, 215]. Fiandaca and
colleagues reported that neuronal exosomes enriched from the blood of AD patients
showed significantly higher levels of Aβ1-42, total tau, p-tau181, and p-tau 396 compared
to the controls[215]. The levels of these candidates were higher in preclinical individuals
up to ten years prior to the clinical onset of AD. Similar results were reported by another
group, claiming that plasma exosomes from AD patient significantly differed from healthy
control based on their morphology, content, and count which might provide a basis for
early diagnosis of AD[216]. In a recent elegant study, a new technology termed amplified
plasmonic exosome (APEX) was developed to Subtype blood exosome-bound Aβ in
relation to cells of origin. The authors found that plasma neuronal exosomes favor binding
to prefibrillar Aβ, specially Aβ1-42. Analyzing these exosomes with APEX presented a
precise correlation to the amyloid plaque load in AD patients with higher sensitivity than
positron emission topography (PET), especially in early stages of AD[217].
Although Astrocyte-derived exosomes (ADE) are reported to be present at lower
levels in plasma compared to neuronal ones (NDE), they contain a higher amounts of APPderived metabolites (including Aβ1-42) and APP-processing enzymes like BACE-1 in
addition to p-tau[218]. This observation allows ADE to distinguish AD patients from the
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study controls. Recently, the components of the complement system have been identified
in plasma astrocytes-derived exosomes, implicating ADE in inflammation and
neurodegeneration in AD[219, 220]

1.3

5xFAD transgenic mouse model
In this work, we use the AD mouse model called 5xFAD. This terminology stems

from the fact that these mice express a total of five AD related mutations. Three of the
mutations are human APP which are the Florida (I716V), Swedish (K670N/M671L), and
London (V717I) while the other two are pertaining PSEN1, namely M146L and L286V.
These genes are regulated by the neural-specific Thy1 promoter, which might explain why
females produce more Aβ than males, probably due to an estrogen response element in the
Thy1 promoter used to drive transgene expression. 5xFAD mice recapitulate the AD
phenotype in several aspects. Intraneural Aβ begins to appear as early as 1.5 months of
age while senile plaques are observed at two months of age[221]. BACE1 increases in
these mice in an age-dependent manner, as well. Gliosis has been reported to accompany
plaque deposition in two month old mice. Senile plaques are observed firstly in the
subiculum and layer V of the cortex, pathology then appears in the cortex and hippocampus
by six months of age[221]. Older mice show plaques in the brainstem, thalamus, and
olfactory bulb. By four months, synaptic degeneration commences, which is determined
by the decrease in presynaptic markers synaptophysin and syntaxin throughout the entire
brain. Post synaptic markers begin to decline by nine months. Lastly, multiple regions of
brain exhibit neuronal loss which starts in areas with severe plaque depositions at about
six months of age.
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Figure1.1: Overview of APP processing. In the non-amyloidogenic pathway, α-secretase
cleaves APP creating sAPPα and CTFα, which is subsequently cleaved by γ-secretase into
P3 and AICD. In the amyloidogenic pathway, APP is first processed by β-secretase, where
sAPPβ is released, followed by cleavage of the CTFβ by γ-secretase to release Aβ.
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Figure 1.2: Overview of exosome biogenesis mechanisms involving MVBs and
IMPCs. Early endosomes mature into multivesicular bodies (MVBs), which are late
endocytic compartments containing intraluminal vesicles (ILVs). Fusion of MVBs with the
plasma membrane results in the release of ILVs into the extracellular space as exosomes.
Other vesicles can be shed from the cell by direct budding from the plasma membrane (e.g.
microvesicles and IPMC derived vesicles). Multiple machineries are involved in the
biogenesis of ILVs, and thus of exosomes, such as ESCRT components, tetraspanins, and
lipids.
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Figure 1.3: Overview of sphingolipid metabolism and related enzymes.
The de novo biosynthetic pathway is initiated in the endoplasmic reticulum by the action
of serine palmitoyltransferase (SPT). Generation of ceramides happens after several
enzymatic reactions. Ceramides are then incorporated into various complex sphingolipids
(predominantly in the Golgi) including ceramide-1-phosphate (C1P), sphingomyelin or
glycoceramides. In sphingolipid catabolic pathways, mostly in lysosomes, sphingomyelin
(also glycosphingolipids and ceramide-1-phosphate) are hydrolyzed, resulting in the
formation of ceramide. Ceramide can then be deacylated to generate sphingosine, which in
turn is phosphorylated to sphingosine-1-phosphate (S1P).
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CHAPTER 2. ASSOCIATION OF AΒ WITH CERAMIDE-ENRICHED
ASTROSOMES MEDIATES AΒ NEUROTOXICITY
2.1

Introduction
Aβ plaque deposits and tau neurofibrillary tangle formation are hallmarks of AD

[222, 223]. However, it is still controversial which of the two factors is critical for neuronal
dysfunction and death, ultimately leading to cognitive decline and demise of the patient.
Most of the previous studies assumed that the buildup of Aβ or tau by themselves induces
neurotoxicity[44, 224, 225] . This assumption, however, was in stark contrast to
observations in AD mouse models and patients showing significant buildup of plaques and
tangles without obvious neuronal cell death[223]. We hypothesized that neuro- toxicity of
Aβ is mediated by its interaction with an unknown factor. Based on our previous studies
showing that Aβ associates with astrocyte-derived exosomes (here termed astrosomes), we
tested if this interaction mediates neurotoxicity of Aβ[164, 226].
Exosomes are generated as intraluminal vesicles of multivesicular endosomes and
secreted as a type of extracellular vesicles by a large variety of cells and tissues[106, 227,
228]. Exosomes are deemed to serve as carriers for the intercellular transport of micro
RNAs and some proteins. Although their size of 100 nm favors a high membrane surfaceto-volume ratio, the role of membrane lipids in exosomes remains largely unexplored[229, 230]. Our laboratory discovered that the sphingolipid ceramide is enriched
in the membrane of astrosomes[164]. We also showed that ceramide mediates association
of Aβ with astrosomes and that this association leads to astrosome aggregation in vitro, a
process we suggested to nucleate amyloid plaques in AD brain [226]. However, we do not
know if amyloid plaque nucleation is the only or even main function of astrosomes. Recent
studies demonstrated that Aβ-associated exosomes cross the blood-brain-barrier and are
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detectable in serum from AD mice and patients[189, 215, 231]. In fact, exosomes purified
from patient serum are proposed as AD biomarkers that are detectable up to a decade prior
to clinical symptoms of cognitive decline[215]. While a proportion of serum exosomes is
clearly derived from brain, composition and function of these exosomes remains largely
unknown.
In the current study using mass spectrometry and anti-ceramide antibody, we found
that a proportion of serum-derived serum exosomes is enriched with the same ceramide
species previously detected in astrosomes isolated from primary astrocyte culture[226].
We also isolated exosomes from wild type and 5xFAD brain tissue and confirmed the
astrocytic origin and Aβ association of tissue and serum-derived exosomes by testing for
the presence of the astrocyte marker glial fibrillary acidic protein (GFAP) and Aβ. Aβassociated astrosomes were taken up by neural cells and specifically transported to
mitochondria, thereby inducing mitochondrial damage and caspase activation. Most
importantly, the concentration of Aβ associated with astrosomes inducing damage was
several orders of magnitude lower than required when using Aβ without astrosomes. Aβassociated astrosomes induced formation of a pro- apoptotic complex between Aβ and
voltage-dependent anion channel 1 (VDAC1), the main ADP/ATP transporter in the outer
mitochondrial membrane[232, 233]. These results suggest that astrosomes are the
unknown factor mediating neurotoxicity of Aβ by inducing mitochondrial damage and
apoptosis. Our data also indicate that Aβ-associated exosomes may comprise a novel
pharmacological target for AD therapy.
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2.2

Methods

Cell cultures: The N2a cell line was obtained from ATCC (CCL-131™). The cells were
grown to 90% confluence at 37 °C and 5% CO2 atmosphere in Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco, Invitrogen, CA, USA) supplemented with 10% fetal
bovine serum (FBS) on 100 mm plates (Corning, MA, USA). For immunocytochemistry
analyses, cells were seeded on poly-L-lysine (Milipore- Sigma, Montana, USA) coated
cover slips at 10,000 cells/cover slip. Cells were gradually deprived of serum to allow for
differentiation into neuron-like cells. Incubation with exosomes was always performed
under serum-free conditions.
Primary neurons were isolated from E16.5-P0 mouse cortices following 30 min
trypsinization and trituration with a flame-polished Pasteur pipet. Neurons were plated on
polyethylene imine coated T-25 flasks as previously described[226] and maintained 7 days
in Neurobasal medium with B27 supplement (Life Technologies) prior to incubation with
exosomes. To cultivate human induced pluripotent stem (iPS) cell-derived neuroprogenitor
(NP) cells, the ReNcell VM Human NP cell line was obtained from Millipore (Temecula,
CA, USA, Cat# SCC008). Cells were maintained according to the supplier’s protocol.
Briefly, cells were expanded on laminin- coated 100 mm tissue culture dishes (Corning) in
ReNcell NSC maintenance medium (Millipore) supplemented with 20 ng/mL fibroblast
growth factor–2 (FGF-2) and 20 ng/mL epidermal growth factor (EGF) (Milli- pore). The
medium was changed daily during the maintenance period. The cells were passaged once
a week using Accutase (Millipore). Cells were then differentiated by seeding them at
around 60% confluency on freshly laminin-coated dishes and growing overnight in the
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presence of growth factors, followed by withdrawal of growth factors. The media were
replaced every other day up to 10 days during the differentiation period.
Serum exosome isolation, quantification, and labeling: All experiments using mice were
carried out according to an Animal Use Protocol approved by the Institutional Animal Care
and Use Committee at University of Kentucky. Sera were isolated from freshly obtained
mouse blood. Human exosomes were isolated from sera obtained from the University of
Kentucky Alzheimer Disease Center.
Mouse blood was drawn through heart puncture and was allowed to clot at room
temperature for 30 min. Blood was then centrifuged at 1800 x g for 10 min at 4 °C. The
clear upper layer was transferred to a fresh tube and centrifuged at 3000 x g for 15 min to
pellet residual blood cells. Exosomes were extracted using ExoQuick exosome solution
(EXOQ; System Biosciences, Inc., Mountain View, CA, USA) according to the
manufacturer’s protocol. Briefly, 250 μl aliquots of serum were treated with 67 μl of
ExoQuick exosome solution, followed by incubation for 60 min at 4 °C to precipitate total
exosomes. Tubes were then centrifuged at 1500 x g for 30 min. Each exosome pellet was
resuspended in 100 μl of PBS with 1X Halt™ Protease Inhibitor Cocktail (Thermo Fisher,
Massachusetts, USA). In certain experiments exosomes were labeled with PKH67
Green Fluorescent Dye using the Green Fluorescent Cell Linker Kit for General Cell
Membrane Labelling (Sigma-Aldrich) according to the manufacturer’s protocol. Briefly,
ExoQuick pellets were resuspended in PBS, 1 ml of Diluent C (CGLDIL, Sigma-Aldrich)
was then added to each sample. As a control, 1 ml of Diluent C after adding the same
volume of PBS was used. Next, 4 μl of PKH67 dye was added to 1 ml of Diluent C then
mixed with the exosomes and the control, PKH67/Diluent C mixture was ultra-centrifuged

33

before being added to samples. The samples were allowed to incubate < 5 min on a rotor
plate. One ml of 1% BSA was then added to bind excess dye. Samples were ultracentrifuged at 110, 000 xg for 70 min, washed and centrifuged again. For exosome
quantification, nanoparticle tracking analysis (NTA) with the ZetaView PMX110 (Particle
Metrix) was used. Briefly, exosomes were resuspended in PBS. Two ml of appropriately
diluted samples were injected into the ZetaView cell. The instrument was set to obtain
NTA measurements at 11 positions, two cycles at each position. During acquisition,
temperature was set to 23 °C, camera sensitivity to 82, 30 frames/s, and shutter speed to
250. Polystyrene beads (100 nm) were used for instrument calibration. For exosome
incubation with ceramide analogs N-oleoyl serinol (S18 or bis palmitoyl ethanolamine
(B16) the exosomes prepared from 5xFAD or control serum were incubated at 37 °C
for 16 h with 50 μM S18 or B16. In addition to the ExoQuick exosome isolation method,
we used the Exoeasy Maxi kit (Qiagen, Germany) to isolate exosomes from sera following
the manufacturer’s protocol. Briefly, sera were diluted with an equal volume of distilled
water to reduce viscosity and they were passed through a 0.45 μm filter to remove larger
particles. 1 volume of Exoeasy binding buffer (XBP) was then added to 1 volume of
sample. Sample/ XBP mix was added onto the Exoeasy spin column and centrifuged at 500
x g for 1 min. Flow-through was discarded and the columns were placed back into the same
collection tube. Ten ml Exoeasy washing buffer (XWP) were then added to columns,
followed by centrifugation at 500 x g for 5 min to remove residual buffer from the column.
Flow-through together with the collection tube were discarded. Spin columns were
transferred to fresh collection tubes. Four hundred μl of elution buffer were added to the
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membrane and incubated for 1 min, followed by centrifugation at 500 x g for 5 min to
collect the eluate.
Brain exosome isolation: This method is a modification to the protocol described by
Miltenyi Biotic for isolation and cultivation of astrocytes from adult mouse brain utilizing
gentleMACS Octo Dissociator. Briefly, mice were anesthetized using isoflurane inhalation
in a chamber followed by perfusion of the whole body with cold 1x PBS to remove bloodderived exosomes from the brain. Mice brains were collected, washed with 1x PBS and cut
into eight sagittal slices using sterile scalpel in a petri dish. Brain slices were then
transferred to C tubes containing enzymatic dissociation buffer. C tubes were tightly closed
and attached upside down onto the sleeves of the gentleMACS Octo Dissociator with
Heaters, Program 37C_ABDK_01 being used. Samples were resuspended and applied to a
MACS SmartStrainer (70 μm) placed on a 50 mL tube. 10 mL of cold D-PBS were applied
onto the MACS SmartStrainer (70 μm). Cell suspensions were centrifuged at 300×g for 10
min at 4 °C, supernatants were carefully transferred to a fresh tube to proceed with exosome
isolation. Supernatants were centrifuged at 2000×g for 10 min followed by 10,000×g for
30–40 min then passed through a 0.45 μm filter before following the Exoeasy exosome
isolation protocol as described above.
Immunocytochemistry: N2a, primary cultured neurons, or human neuroprogenitor cells
were seeded on poly-L-lysine coated cover slips at a density of 25,000 cells/cover slip. N2a
cells were allowed to differentiate by gradual serum deprivation[234]. Two days prior to
exosome incubation, exosome-free FBS (EXO-FBS - System Biosciences, Mountain
View, CA, USA) was used to supplement the media. Cells were then incubated with
exosomes and washed three times with PBS, followed by fixation with 4% p-formaldehyde
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containing 0.5% glutaraldehyde in PBS for 15 min at room temperature. Permeabilization
was performed by incubation with 0.2% Triton X-100 in PBS for 5 min at room
temperature. Non-specific binding sites were blocked with 3% ovalbumin/PBS for 1 h at
37 °C. Cells were then incubated with primary antibodies at 4 °C overnight. The next day,
cells were washed with PBS and incubated with secondary antibodies diluted 1: 300 in
0.1% ovalbumin/PBS for 2 h at 37 °C. Secondary antibodies were Cy2-conjugated donkey
anti-mouse IgM, Alexa Fluor 546-conjugated donkey anti-rabbit IgG, and Alexa Fluor 647conjugated goat anti-mouse IgG (Jackson ImmunoResearch, West Grove, PA). After
washing, cover slips were mounted using Fluoroshield supplemented with DAPI (SigmaAldrich) to visualize the nuclei. We used the following primary antibodies: anti-ceramide
rabbit IgG (1:100, our laboratory), anti- flotillin-2 mouse IgG (1:300 BD Biosciences,
California, USA, 610383), anti-amyloid-beta mouse IgG 4G8 clone (1:200 Biolegends,
California, USA, SIG-39220), beta amyloid recombinant rabbit monoclonal antibody
(H31L21, Thermo Fisher), anti-GFAP mouse IgG (1:500, abcam, Cambridge, MA, USA,
ab10062), anti-Tom 20 rabbit IgG (1200, Santa Cruz, sc-11415), anti-VDAC1 rabbit IgG
(1500, Abcam, ab15895). Fluorescence microscopy was performed using Eclipse Ti2-E
inverted microscope system (Nikon, New York, USA). Images were processed using
Nikon NIS-Elements software equipped with a 3D deconvolution program. Pearson’s
correlation coefficient for two fluorescence channels in overlays was used to assess the
degree of colocalization.
Proximity ligation assay: Cells were grown and treated as described above in the protocol
for immunocytochemistry. Non-specific binding sites were blocked with Duolink PLA
blocking solution (Sigma-Aldrich) for 1 h at 37 °C. The primary antibodies used were;

36

anti-Aβ mouse IgG (1:500 4G8, Biolegends, California, USA, SIG-39220), anti-VDAC1
rabbit IgG (1:1000 abcam, Cambridge, MA, USA, ab34726) Secondary PLA probes: antimouse MINUS affinity-purified donkey anti-mouse IgG (H + L) and anti-rabbit PLUS
affinity-purified donkey anti-rabbit IgG (H + L) were diluted 1:5 in antibody diluent buffer
and samples incubated for 1 h at 37 °C followed by ligation and amplification steps as
described in the manufacturer’s protocol (Duolink, Sigma-Aldrich). Cover slips were
mounted using Fluoroshield supplemented with DAPI (Sigma-Aldrich) to visualize the
nuclei. Images obtained with secondary antibody only were used as negative controls
representing the background intensity in a laser channel. ImageJ software
(https://imagej.nih.gov/ij/) was used to analyze the pictures. Two channels (DAPI and
TRITC) were separated to analyze nuclear staining (DAPI) of the images separately from
the TRITC channel associated with the PLA dots. Firstly, threshold was set in order to
identify nucleus and to allow for binary conversion (black and white). Morphological
function was used to separate touching nuclei. Nuclei were counted and added to the region
of interest (ROI) where the appropriate minimum and maximum pixel area sizes were set.
In the other channel, the number of dots (PLA signals) in each cell as identified by labeling
of nuclei was calculated with the “Measure” command from the ROI manager using single
point as an output type.
Isolation of mitochondria: N2a cells were seeded on 100 mm dishes at 35–40% of density,
followed by incubation with wild type or 5xFAD serum exosomes. Sixteen hours later,
cells were harvested and washed twice with ice-cold PBS. Cell pellets were then transferred
into a Dounce homogenizer and disrupted with 2 ml of ice-cold mitochondria extrac- tion
buffer [10 mM HEPES, 125 mM sucrose, 0.01% BSA, 250 mM mannitol, 10 mM EGTA,
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and protease inhibitors (pH 7.2)]. The homogenates were transferred into a centrifuge tube
and cell debris pelleted at 700 x g at 4 °C for 10 min to enrich for mitochondria. Following
centrifugation under same conditions, supernatants were transferred to a new ice-cold tube,
and then mitochondria pelleted at 10,000 x g for 15 min at 4 °C. The mitochondrial pellet
was resuspended in 1 ml of lipid binding buffer [20 mM Tris-HCl, 150 mM NaCl, 1 mM
EDTA (pH 7.5), and 1% digitonin, supplemented with protein inhibitor cocktail (Roche)].
Complete lysis of mitochondrial membranes was achieved by sonication. Removal of
insoluble debris was achieved by centrifugation at 10,000 x g for 15 min at 4 °C. The
protein concentration in the supernatants from untreated cells and treated cells was
determined using Bio-rad RC DC™ Protein Assay.
FLICA and cytotoxicity assay: The FLICA 660 Poly Caspase Assay Kit
(ImmunoChemistry Technologies, Minnesota, USA) was used to determine the presence
of early caspase activation. This in vitro assay employs the fluorescent inhibitor probe 660VAD-FMK to label active caspase enzymes in living cells. N2a cells (0.25–1·105) were
incubated with exosomes (0.5–1x104 exosomes/cell) for 6 h at 37 °C. The cells were
washed twice with PBS and resus- pended in RPMI medium with 10% FBS before staining
with 30 × FAM-VAD-FMK for 30 min at 37 °C. Cells were washed with 1 x apoptosis
wash buffer prior to being fixed with 4% paraformaldehyde supplemented with 0.5%
glutaraldehyde. The assay was then followed by PLA as described above.
For LDH cytotoxicity assays, N2a cells were seeded at a density of 5000 cells/well on 96well plates in complete culture medium and were allowed to grow to adequate confluency.
One day before incubation with exosomes, media were replaced with 2% EV-depleted FBS
and kept overnight. Cells were treated for 12 h with 1 x 104 exosomes /cell. LDH release
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was detected using the CyQUANT™ LDH Cytotoxicity Assay (Thermo Fisher Scientific,
Waltham, MA, USA) according to the manufacturer’s protocol.
Western blot and dot blot: For Western blot analysis, samples were mixed with an equal
volume of 2X Laemmli sample buffer. Samples were resolved by SDS gel electrophoresis
on polyacrylamide gels and transferred to nitrocellulose membrane (Hybond ECL,
Amersham Biosciences, UK). Non-specific binding sites were blocked with 5% fat-free
dry milk in PBS containing 0.05% Tween-20 followed by overnight incubation with
primary antibodies. For exosome characterization we used CD9, CD63, CD81 rabbit
antibodies from ExoAb Antibody Kit (System Biosciences, Inc., Mountain View, CA,
USA) after dilution to 1:1000. The following primary antibodies were used for
immmunolabeling on Western blots: anti-flotillin-2 mouse IgG (1:1000, BD Biosciences,
California, USA, 610383), anti-cleaved caspase-3 rabbit IgG (Cell Signaling, Danvers,
MA, USA, #9664), anti-VDAC1 goat poly- clonal IgG (1: 200, Santa Cruz Biotechnology,
Inc., CA, USA), anti-Drp-1 mouse IgG1 kappa light chain (Santa Cruz, Dallas, TX, USA,
sc-271,583). Signals were detected using either pico or femto chemiluminescent (ECL)
horseradish peroxidase (HRP) substrate (Thermo Fisher, Massachusetts, USA). Blot
images were developed using Azure c600 system (Azure Biosystems, California, USA).
Exosome immune capturing on beads: affinity purification using ceramide beads
Twenty μL of protein A sepharose conjugated magnetic beads were pre-blocked with FcR
Blocking Reagent (MACS, Miltenyi Biotec) for 1 h at room temperature. After 3-times
washing with lipid biding buffer [20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA (pH 7.5)],
either anti-ceramide rabbit IgG or control non-specific rabbit IgG were immobilized on the
beads in 1% BSA. Approximately 2 μg were added to each sample and the reaction kept
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mixing overnight on a rotary plate. Next day, beads were washed 3-times and diluted
exosome samples were added and allowed to incubate with the beads for 2 h at room
temperature. Beads were then collected using magnetic columns and washed 3-times with
deter- gent free lipid binding buffer. The beads were incubated with an adequate volume
of 2x sample Laemmli buffer, heated at 90 °C for 10 min and processed for immunoblot
labeling of GFAP. Aliquots of the flow through were used for dot blots determining Aβ
content and the residual sample processed for Western blot using 4 x sample Laemmli
buffer. Equal volumes of the samples were then applied to each well for Western blot
analysis. 4 μL were used for dot blot with the flow through of each sample.
Mass spectrometric analysis of lipids: Exosomes prepared from serum were taken up in
water and ceramide species were quantified in the sphingolipidomic (LC-MS/MS) analysis
core facility at the Medical University of South Carolina, Charleston, SC. The lipid
concentration was normalized to lipid phosphate and exosome number.
Statistical analysis: Clustering analyses were performed with Particle Explorer V2.1.4
(Particle Metrix Inc., Germany) using the following features (1. Particle size 2. Position 3.
Area std. 4. Mean intensity std. 5. Trajectory total distance, std. speed, track time, medspeed, and max-speed). For the lipid analysis, results were analyzed with Two-way
ANOVA using ceramide species and genetic background as two independent factors. The
effect of exosomes from two sources (e.g., wild type and 5xFAD) with unequal sample
sizes or unknown variances were analyzed by unpaired t-test with Welch’s correction.
When multiple comparisons affected by a potential baseline shift in each sample (e.g., mass
spectrometric analysis of ceramide species) were analyzed, we used the Bonferroni
correction on One-way ANOVA, a statistical test typically applied to mass spectrometric
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analyses to exclude false positives. Other tests such as One-way ANOVA with StudentNewman-Keuls (SNK) post hoc test or Tukey correction for comparison of multiple means
were applied when used for similar analyses as described in literature. Results showing p
< 0.05 were reported as statistically significant. All statistical analysis was done on Graphpad prism software.

2.3
2.3.1

Results
5xFAD mouse and AD patient serum contains exosomes enriched with ceramide
and derived from astrocytes (astrosomes)

Several studies showed that exosomes cross the blood- brain-barrier (BBB)
carrying toxic and misfolded protein of CNS origin[215, 235]. These studies also showed
that purification of exosomes from serum or plasma allows characterization of exosomes
from different cell types in the brain, including astrocytes. We used polymer precipitation
and membrane affinity chromatography to isolate exosomes from sera of transgenic mouse
model of AD and AD patients as these isolation methods were shown to give consistent
results when used with plasma or serum[108, 236, 237]. Due to the limitations in
availability of AD patient serum, we first focused on characterization of exosomes
prepared from serum of the transgenic mouse model of AD (5xFAD) and wild type
littermates with identical genetic background (C57Bl/6). 5xFAD mice overexpress
presenilins (PS1) with two FAD mutations (M146L and L286V) as well as amyloid
precursor

protein

(APP)

with

three

FAD

mutations

(V717I,

I716V,

and

K670N/M671L)[221]. Nanoparticle tracker analyses (NTA, Zetaview) and cluster
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analyses software (Particle Explorer, Particle Metrix, Mebane, NC) showed that the
number of exosomes in wild type and 5xFAD serum from 9 months old mice was similar
(8.47x1011 +/− 3.6x1010 exosomes/250 μl serum vs. 9.14x1011 +/− 5.1x1010
exosomes/250 μl serum, N = 6). While the majority of exosomes from wild type serum
was composed of a homogenous population of vesicles with medium size of 100 nm (Fig.
2.1a), exosomes from 5xFAD serum contained an additional vesicle population of larger
size accounting for 37 +/- 4% of the total population, indicating aggregate formation (Fig.
2.1b). Immunoblot analysis was used to validate the presence of exosomal markers such
as tetraspanin proteins (CD63, C9, and CD81 as well as raft and exosome- associated
proteins flotillin-1 and flotillin-2, and the astrocyte marker GFAP (Fig. 2.1c).
Lipid analysis using mass spectrometry (LC-MS/MS) showed that 5xFAD exosomes
were enriched with ceramide (4.3 pmoles total ceramide/1011 5xFAD serum exosomes vs.
2.2 pmoles/1011 wild type serum exosomes), particularly C16:0, C18:0, C20:0, 22:0,
C24:0, and C24:1 ceramide (Fig. 2.1d and e, N = 3). Normalization to lipid phosphate
(Fig. 1d) as well as particle count (Fig. 2.1e) showed similar enrichment, confirming that
the ceramide composition was representative for the exosome population in serum. We
also determined ceramide composition and GFAP association of exosomes in serum from
AD patients. Consistent with the results obtained with mouse serum, the number of
exosomes in serum from healthy controls and AD patients was similar (2.05x1011 +/−
5.1x109 exosomes/250 μl serum vs. 1.85x1011 +/− 6.2x109 exosomes/250 μl serum. N =
3). There was a population of larger particles which appeared to be similar to that

in

5xFAD serum (Fig. 2.11A). Fig. 2.11b shows that the levels of some of the ceramide specie
(C16:0,

C18:0, C18:1, C20:0,

and C20:1 ceramide) were increased in AD patient
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exosomes, while others (C22:0 and C24:0 ceramide) were not. This difference in the
ceramide profiles between the 5xFAD mouse and AD patient serum exosomes could be
due to differences in the activity of ceramide synthases (CerS) in mice vs. patients. The
GFAP level associated with serum exosomes from AD patients was comparable to that of
healthy controls (Fig. 2.11C). It is possible that characteristics such as exosome enrichment
with GFAP are more profound with 5xFAD serum exosomes because of the severe AD
pathology phenotype that may not be completely comparable to that of late onset AD
patients. Therefore, our results suggest that the main difference between 5xFAD and AD
serum exosomes to those from wild type and human controls is a proportion of exosomes
enriched with particular ceramides.

2.3.2

Serum astrosomes are associated with Aβ and sensitive to novel ceramide analogs
To further characterize the proportion of ceramide- enriched exosomes, we used

anti-ceramide rabbit IgG immobilized on protein A sepharose beads to separate ceramideenriched exosomes from other exosome populations in serum. Figure 2.2a shows that
GFAP labeling was only found with exosomes bound to the beads, while exosomes in the
flow through were GFAP negative. Control rabbit IgG did not bind any serum-derived
exosomes confirming specificity of the binding reaction for ceramide-enriched astrosomes.
Wild type serum also contained astrosomes retained by anti-ceramide antibody, however,
at lower concentration as indicated by weaker immunolabeling for GFAP. NTA analysis
showed that retention by anti-ceramide beads reduced the number of exosomes by 2.3+/−
0.3% from wild type and 9.2+/− 0.8% (N = 3) from 5xFAD serum indicating that the
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proportion of ceramide-enriched astrosomes in 5xFAD serum is ≃ 4-fold higher than that
in wild type serum.

Next, we tested if ceramide-enriched exosomes in serum were associated with Aβ by
determining the amount of Aβ retained on anti-ceramide beads vs. that in flow through.
Immunolabeling using dot blots showed that only the flow through of beads with control
IgG contained Aβ42, while amyloid peptide was retained on anti-ceramide beads (Fig.
2.2b). Consistent with immunolabeling for GFAP, the amount of Aβ was 2.2-fold higher
in 5xFAD serum than that from wild type mice (not shown). Since ceramide-enriched
exosomes were associated with GFAP as well as Aβ we concluded that 5xFAD serum
contained a proportion of astrosomes enriched with ceramide and associated with Aβ.
Enrichment of astrosomes with ceramide suggested that this lipid participates in
association of Aβ to astrosomes. This hypothesis is consistent with our previous studies
showing that anti-ceramide IgG prevented aggregation of exosomes induced by incubation
with Aβ. Figure 2.2c shows that incubation with anti- ceramide IgG abolished the
proportion of larger sized vesicles in the preparation of 5xFAD exosomes, similar to the
effect of anti-ceramide antibody on aggregation of Aβ-associated astrosomes derived from
cell culture media. We also found reduction of vesicle size by 17% (N = 4) when adding
the novel ceramide analog N-oleoyl serinol (S18) but not N-palmitoyl bisethanolamine
(B16, structures are shown in Fig. 2.11 D) to 5xFAD exosomes, suggesting that S18 is a
ceramide mimic that disrupts Aβ association and aggregation of astrosomes, probably by
interfering with the ceramide- mediated binding of Aβ to astrosomes.
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2.3.3

Astrosomes are taken up by neural cells and transport Aβ and ceramide to
mitochondria.
To test if serum-derived exosomes are up taken by neural cells, we incubated

neuronally differentiated N2a cells, a mouse neuroblastoma cell line, with exosomes
labeled with the fluorescent membrane-binding dye PKH67. N2a cells were used as an in
vitro model since neuroblastoma cells are an established model for neuronal uptake and
biological activity of exosomes[238, 239]. Key results were then confirmed using primary
cultured neurons. Fig. 2.12A-C shows that both, wild type and 5xFAD serum-derived
exosomes labeled with PKH67 are taken up by N2a cells and primary cultured neurons.
Cells incubated with wild type serum-derived exosomes were labeled for ceramide, but
not or only weakly for GFAP (Fig. 2.3a and c), while cells incubated with 5xFAD serum
exosomes were colabeled for ceramide and GFAP (Fig. 2.3b and c). Since there were no
or only few cells that showed increased ceramide signals without being colabeled for
GFAP, our data demonstrate that N2a cells effectively take up ceramide-enriched
astrosomes.
Next, we tested whether astrosomes transported Aβ into N2a cells. Using
immunocytochemistry, we detected Aβ signals in N2a cells incubated with 5xFAD
exosomes but not with those from wild type serum (Fig. 2.3d and e). The Aβ signal
colocalized with labeling for flotillin-2 (arrows in Fig. 2.3e), suggesting that astrosomes
delivered Aβ into N2a cells. To further confirm the validity of these results, we used a
proximity ligation assay (PLA) for complex formation between ceramide and Aβ in
membrane dye PKH67-labeled exosomes taken up by N2a cells[240, 241]. Fig. 2.13A-D
shows that PLA signals colocalized with PKH67 labeling and were only observed in cells
incubated with 5xFAD exosomes.
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We then tested if serum exosomes from AD patients showed similar uptake
characteristics as 5xFAD exosomes. N2a cells incubated with AD patient exosomes
showed colocalization of ceramide and flotillin-2 (Fig. 2.4b). While endogenous ceramide
and flotillin-2 were detectable in exosome-treated cells, we lowered the pertinent
fluorescence signals to that of background to specifically monitor ceramide and flotillin-2
contributed by exosomes. Cells incubated with exosomes from healthy controls showed
ceramide and flotillin-2 and ceramide labeling, however, at much lower intensity than cells
incubate with AD exosomes (Fig. 2.4a). These results indicated that exosomes from human
serum, particularly when derived from AD patients, were taken up and transported
ceramide into cells.
Several studies showed that mitochondria are affected by Aβ[42, 242, 243].
Using immunocytochemistry for Aβ and Tom-20, we showed that Aβ was labeled in
mitochondria of hippocampal tissue from AD patients (arrows in Fig. 2.14A), suggesting
that Aβ is transported to mitochondria in AD brain. To investigate exosome-mediated
transport of Aβ, we first tested if 5xFAD serum-derived exosomes are transported to
mitochondria. Figure 2.5a, b and e show that the exosome marker flotillin-2 colocalized
with the mitochondrion marker Tom-20 in 5xFAD exosome-incubated N2a cells. The
flotillin fluorescence signal was analyzed after subtracting intrinsic signals, thereby
eliminating the possibility that the colocalization resulted from the fluorescence signal of
endogenous flotillin with mitochondria. Colabeling and Pearson’s coefficient for
colocalization were significantly, but only moderately (about 20%) lower when exosomes
from wild type serum were used (Fig. 2.5b and e), suggesting that transport of exosomes
to mitochondria is not critically dependent on Aβ association.

46

We then tested if serum-derived exosomes from AD patients and healthy
controls matched for sex, age, and body matrix index (BMI) transported Aβ to
mitochondria in neurons differentiated from human iPS cells. Figure 2.5d and f shows that
Aβ colocalized with Tom-20 in AD patient exosome-treated N2a cells, while there was no
Aβ signal detectable when cells were incubated with serum exosomes from healthy
controls (Fig. 2.5c and f). AD patient exosomes labeled with Vybrant CM diI also
colocalized with Aβ and Tom-20, demonstrating that exosomes effectively transported Aβ
to mitochondria (Fig. 2.5g). Mitochondria appeared to be clustered, suggesting that uptake
of AD patient-derived exosomes led to mitochondrial damage in neurons.

2.3.4

Astrosomes induce Aβ-VDAC1 complex formation, which activates caspases
Our observation that 5xFAD mouse and AD patient serum exosomes

induced clustering of mitochondria in N2a cells and primary cultured neurons prompted
us to investigate if Aβ-associated astrosomes are neurotoxic by inducing mitochondrial
damage. To test if astrosomes themselves were neurotoxic we analyzed mitochondrial
clustering and fragmentation of neuronal processes, and performed TUNEL assays after
incubation of primary cultured neurons from mouse brain with astrosomes, Aβ, and Aβ
pre-incubated with astrosomes (Fig. 2.6a-f). The number of TUNEL positive cells was
increased by 2.6-fold (Fig. 2.6f) when cells were incubated with Aβ- associated
astrosomes, concurrent with mitochondrial clustering (arrows in Fig. 2.6e) and 5.9-fold
enhanced fragmentation of neuronal processes (Fig. 2.6c) as determined by β-tubulin
labeling. This result showed that astrosomes themselves were only marginally toxic, but
they significantly enhanced neurotoxicity of Aβ.
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Mitochondrial dysfunction is known to be a critical factor in induction of
neurotoxicity leading to neurodegeneration in AD[244-246]. One of the previously
described targets for Aβ is mitochondrial voltage-dependent anion channel 1 (VDAC1), a
mitochondrial gatekeeper for ADP/ATP and calcium localized in the outer mitochondrial
membrane[232, 233]. We tested if astrosome-associated Aβ interacted with VDAC1 and
induced mitochondrial dysfunction. PLAs using antibodies to VDAC1 and Aβ showed a
6-fold in- crease in the number of signals indicating complex formation between VDAC1
and Aβ when N2a cells were incubated with exosomes from 5xFAD serum as compared
to those from wild type serum (Fig. 2.7a-c). PLA signals were clustered (arrows in Fig.
2.7b) consistent with mitochondrial clustering induced by Aβ-associated astrosomes.
Mitochondrial damage was confirmed by upregulation of the fission protein Drp-1 in
mitochondria isolated from N2a cells incubated with 5xFAD serum exosomes (Fig. 2.7d).
Figure 2.7e and f shows that in N2a cells and primary cultured neurons incubated with
exosomes from 5xFAD mice or AD patient serum, PLA signals were colocalized with
Tom-20, concurrent with mitochondrial clustering. These results confirm that astrosomeassociated Aβ formed complexes with mitochondrial VDAC1 and leads to mitochondrial
damage. PLA signals for VDAC1-Aβ complexes were also found in the vicinity of
amyloid plaques of AD brain tissue, suggesting that VDAC1-Aβ complex formation
contributes to AD pathology in vivo (Fig. 2.14B).
Since 5xFAD mouse and AD patient serum exosomes transported ceramide
into cells (Figs. 2.3b and 2.4b) we tested if VDAC1-Aβ complex formation was
colocalized with ceramide. Figure 8a-c shows that in primary cultured neurons incubated
with 5xFAD serum exosomes (Fig. 2.8b) or AD patient exosomes (Fig. 2.8c), PLA signals
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for formation of complexes of VDAC1 with Aβ were colocalized with ceramide (arrows).
Neurons incubated with wild type serum exosomes showed no or only a few PLA signals
and they were not colocalized with ceramide (Fig. 2.8a). This result suggested that
VDAC1-Aβ complex formation was associated with ceramide derived from exosomes.
Next, we tested if exosome-mediated VDAC1-Aβ complex formation led to
activation of caspase 3, a hallmark of neurotoxicity and apoptosis. Figure 2.9a and b shows
that in N2a cells incubated with AD patient serum (Fig. 2.9a) or 5xFAD mouse serum (Fig.
2.9b) exosomes, PLA signals for VDAC1-Aβ complexes were colocalized with labeling
for activation of caspases (FLICA assays), suggesting induction of apoptosis.
Activation of caspases was confirmed by immunoblot analysis for cleaved
caspase 3 (Fig. 2.9d and e). Since the Aβ content of 5xFAD serum exosomes was
approximately 25 pg Aβ42/1012 exosomes (calculations based on ELISA data, not shown),
and 1 x 104 exosomes/cell were added to 1 x 105 cells in 1 ml of medium, the apparent Aβ
concentration was 5 fmoles/l, which is several orders of magnitude less than what is
commonly used in Aβ neurotoxicity assays. VDAC1-Aβ complex formation concurrent
with caspase 3 activation was confirmed with 5xFAD serum exosomes and primary
cultured neurons (Fig. 2.9c), suggesting that association of Aβ to ceramide-enriched
exosomes enhances Aβ neurotoxicity by inducing mitochondrial damage and caspase 3
activation.
Finally, we compared neurotoxicity of 5xFAD serum exosomes with those
from mouse brain tissue before and after removal of ceramide-enriched astrosomes using
pull down with anti-ceramide antibody. Exosomes were isolated from brain tissue after
perfusion with PBS to rule out any contamination with serum exosomes. Analyses using
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NTA showed that brain tissue-derived exosomes from wild type and 5xFAD mice were
similar in number (1.5 × 109 exosomes/mg wild type vs. 1.6 × 109 exosomes/mg 5xFAD
brain tissue) and size distribution (Fig. 2.10a). Normalized to exosome number, the wild
type and 5xFAD exosomes contained comparable levels of exosome markers, however,
GFAP levels were higher in 5xFAD exosomes indicative of a higher proportion of
astrosomes in 5xFAD brain tissue (Fig. 2.10b).
Next, we tested if brain tissue-derived exosomes showed similar effects on
neuronal apoptosis as serum exosomes. Results of the FLICA assay (Fig. 2.10c) show that
induction of apoptosis by incubation with 5xFAD brain exosomes (0.5 × 104
exosomes/cell) was about 3- fold higher than that with wild type brain exosomes,
consistent with data obtained with exosomes from serum (Fig. 2.9). When testing
cytotoxicity using a CyQuant assay we found that normalized on the same number of
exosomes used per cell (1x104 exosomes/cell) toxicity of exosomes from 5xFAD brain
was 4-fold higher than that from wild type brain and 3.5-fold higher than that from 5xFAD
serum exosomes. This result shows that the number of neurotoxic exosomes is highly
elevated in 5xFAD brain and that serum exosomes represent a portion of brain exosomes
with increased neurotoxicity. When we removed the portion of ceramide-enriched
exosomes from 5xFAD and wild type brain tissue and serum, cytotoxicity dropped by half,
demonstrating that enhancement of Aβ neurotoxicity is mediated by enrichment of Aβassociated astrosomes with ceramide.
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Figure 2.1: 5xFAD serum-derived exosomes are enriched with ceramide and
associated with GFAP. (a-b) Cluster analysis of wild type (WT) and 5xFAD serumderived exosomes after Nano Particle Tracking analysis showing a population of larger
exosomes in 5xFAD serum. N = 3 (c) Immunoblot of exosome markers CD9, CD63, CD81,
flotillin-1, and flotillin-2, demonstrating higher amounts of GFAP in 5xFAD exosomes
compared to WT exosomes. d-e Ceramide species profile determined using LC-MS/MS of
WT and 5xFAD serum-derived exosomes and normalized to lipid phosphate content (d)
and to exosome count (e) Asterisks denote significance (p < 0.05) after Two-way ANOVA
followed by Bonferroni correction (N = 3).
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Figure 2.2: 5xFAD serum astrosomes associated with Aβ form aggregates, which is
reduced by the novel ceramide analog S18. (A) Gel electrophoresis after immune
capturing of exosomes on beads using either ceramide antibody or control IgG and probing
with anti-GFAP antibody. Blot is representative of the results from three independent
experiments. (B) Dot blot against Aβ using flow through for the same experiment. (C) Size
distribution of wild type (WT), 5xFAD, and 5xFAD exosomes treated with anti-ceramide
IgG. (D) Size distribution of WT, 5xFAD, and 5xFADexosomes treated with the novel
ceramide analog S18. Particle diameter of each sample is represented as ±SEM, two-way
ANOVA, *p < 0.05. N = 4
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Figure 2.3: 5xFAD serum contains Aβ-associated astrosomes that are taken up by
neural cells. Representative images of N2a cells incubated with exosomes isolated from
wild type (WT) (a, d) or 5xFAD serum (b, e)and coimmunolabeled with antibodies against
GFAP and ceramide (a, b) orflotillin-2 and Aβ (d, e). Arrows point at cells with uptake of
Aβ-associated exosomes. The Pearson’s correlation coefficient was calculated to compare
colocalization of GFAP and ceramide (c) or flotillin-2 and Aβ signals (f) in WT (open bar)
and 5xFAD (closed bar). Welch’s t-test, *p < 0.05. N = 6
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Figure 2.4: Serum-derived exosomes from AD patients transport ceramide into cells.
Immunofluorescence images of N2a cells incubated with either (a)healthy control or (b)
AD patient serum-derived exosomes labeled with anti-ceramide and flotillin-2 antibodies.
(c) fluorescence intensities for the ceramide signal. N = 6. Student t-test with Welch’s
correction, *p < 0.05, **p < 0.01.
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Figure 2.5: Serum-derived exosomes from 5xFAD mice and AD patients’ shuttle Aβ
to mitochondria in N2a cells and neurons. Immunofluorescence images of N2a cells
incubated with either (a) wild type or (b) 5xFAD serum-derived exosomes and then labeled
with flotillin-2 and Tom-20 antibodies. (e)Pearson’s correlation coefficient for
colocalization of flotillin-2 and Tom-20. N = 6. Student t-test with Welch’s correction. *p
< 0.05. c, d Neurons differentiated from human iPS cells and incubated with control healthy
human (c) or AD patient exosomes (d) showing that only AD patient exosomes shuttle Aβ
to mitochondria in neurons (arrows). f Pearson’s correlation coefficient for colocalization
of Aβ with Tom-20. N = 6. Student t-test with Welch’s correction. **p < 0.01. g as in d,
but additional labeling of AD patient exosomes with Vybrant CM diI showing
mitochondrial clustering (arrows) induced by Aβ-associated exosomes. Bottom image
shows detail of (g)
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Figure 2.6: Neurotoxic effect of Aβ42/astrosome complexes on primary neuronal
cultures. Representative single-focal-plane images of β-tubulin and Tom-20 labeling
obtained with control (a), Aβ42 (b), astrosome (d), or Aβ42/astrosome-incubated (e)
primary cultured mouse neuron. Arrows indicate mitochondrial clusters. c Average
normalized density of β-tubulin labeling reveals that the greatest loss occurs in cultures
treated with Aβ42/astrosome complexes. N = 6. One-way ANOVA with Student-NewmanKeuls (SNK) post hoc test). ***p < 0.001, **p < 0.005, *p < 0.05). f TUNEL assay detected
a 2.6-fold increase in neuronal cell death when Aβ42 and astrosomes were combined (N =
4. One-way ANOVA with SNK post hoc test)
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Figure 2.7: Aβ-associated exosomes mediate complex formation between VDAC1 and
Aβ and induce mitochondrial damage. a, b Representative immunofluorescence images
of N2a cells incubated with wild type exosomes (a) or 5xFAD exosomes (b) showing
increased number of PLA signals in cells incubated with 5xFAD exosomes. Right panels
show detail from left panel (frame). Each red dot denotes complex formation between Aβ
and mitochondrial VDAC1. Arrows indicate PLA signals in mitochondrial clusters (c)
Calculation and comparison of average PLA signals per cell between wild type and 5xFAD
incubations, six images for each condition. Student t-test followed by Welch’s correction.
N = 6. p <0.001 (d) Western blot of mitochondrial protein from N2a cells using antibody
against Drp-1 and VDAC1 as a reference protein. e, f Colocalization between PLA signals
for VDAC1-Aβ complexes and mitochondrial marker Tom-20 labeling in N2a cells and
primary cultured neurons incubated with 5xFAD serum exosomes (e) and AD patient
serum exosomes (f).
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Figure 2.8: Exosome-induced VDAC1-Aβ complex formation is associated with
ceramide. Representative immunofluorescence images for PLA signals fromVDAC1-Aβ
complexes and ceramide in primary cultured neurons incubated with wild type mouse
exosomes (a), 5xFAD mouse exosomes (b), or human AD patient serum-derived exosomes
(c). Images in right panel are details at higher magnification (frames in left panel) with
arrows pointing at PLA signals colocalized with ceramide
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Figure 2.9: 5xFAD and human AD patient serum-derived exosomes trigger apoptosis
in cells induced by interaction between mitochondrial VDAC1 and Aβ. Representative
immunofluorescence images of N2a cells incubated with (a) AD patient exosomes or (b)
5xFAD mouse serum-derived exosomes. FLICA assays were followed by PLAs for
VDAC1-Aβ complex formation. Images show that cells with VDAC1-Aβ complexes
undergo apoptosis(arrows). c Primary cultured neurons incubated with 5xFAD serum
exosomes followed by FLICA assays and PLAs. Arrows indicate neurons colabeled for
VDAC1-Aβ complexes and caspase 3 activation. These cells show pyknic nuclei
(condensed DAPI labeling) indicative of apoptosis. (d)Western blot with N2a cell lysate
immunolabeled for cleaved caspase 3 using GAPDH as a reference protein. Blot is
representative of three independent experiments. e Relative fold expression of cleaved
caspase 3 normalized to GAPDH. One-way ANOVA followed by Tukey correction. N =
3. **p < 0.001
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Figure 2.10: Ceramide-enriched 5xFAD brain tissue and serum exosomes are
neurotoxic. (a) Cluster analysis of wild type (WT) and 5xFAD brain tissue derived
exosomes after Nano Particle Tracking analysis. N = 3 (b) Immunoblot of exosome
markers flotillin-1, Alix-1, CD9, and GFAP, demonstrating higher amounts of GFAP in
5xFAD exosomes compared to WT exosomes. c FLICA assay shows 3-fold increased rate
of apoptosis induction (cells with activated caspase 3) after incubation for 12 h of N2a cells
with 5xFAD brain tissue exosomes compared to WT exosomes .N = 15, Student t-test with
Welch’s correction p < 0.005. d Cytotoxicity (CyQuant) assay shows reduction of
neurotoxicity after depletion of ceramide-enriched exosomes. N = 7, Multiple Student ttest with Welch’s correction p < 0.05.
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Figure 2.11: Serum-derived exosomes from AD patients are enriched with ceramide.
(A) Size distribution (Zetaview NTA analysis) of human serum exosomes. (B) Ceramide
species profile using lipid mass spectrometry (LC-MS/MS) of AD patient serum-derived
exosomes normalized to phosphate content. (C) Immunoblot for exosome markers CD63
and Flotillin-1 showing equal protein expression levels of GFAP in AD and healthy control
individuals. (D) Structures of ceramide analogs S18 and B16.
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Figure 2.12: Serum derived exosomes from WT and 5xFAD mice are taken up by N2a
cells. Representative fluorescence microscopy images of PKH67-labeled exosomes from
wild type (A) and 5xFAD (B) mice showing their uptake by N2a cells and primary cultured
neurons (C, wild type; D, 5xFAD exosomes).
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Figure 2.13: 5xFAD exosomes retained complex formation between Aβ and ceramide
after uptake into N2a cells. Either wild type (A) or 5xFAD (B, C, D) serum-derived
exosomes were labeled with PKH67 dye and then then used for incubation of N2a cells.
PLA shows complex formation between Aβ and ceramide only with 5xFAD exosomes. C
is similar to B at higher magnification. D is detail (frame) from C.
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Figure 2.14: Interaction between Aβ and mitochondrial via VDAC1 in human brain.
(A) Representative flouresence image of human brain section showing colocalization of
Aβ with mitochondrial Tom20 aroung amyloid plaque (arrows). (B) PLA using antibodies
against Aβ and mitochondrial VDAC1 showing complex formation in cells surrounding
amyloid plaque.
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2.4

Discussion
While accumulation of Aβ is a hallmark in human AD, its causal role in

neurotoxicity and cognitive decline is persistently elusive. Other factors such as tau,
bacterial or viral infection, insulin resistance, and neuroinflammation are invoked in AD,
and yet none of these factors was proven critical in the onset of the disease or
neurodegeneration[247-249].

Probably

the

most

likely

explanation

for

AD

pathophysiology is a multifactorial cascade of events with any of these factors initiating
or amplifying each other during the course of the disease. This multifactor hypothesis
implies that each factor is necessary, but not sufficient to initiate AD or cause
neurotoxicity. The idea that Aβ or tau require additional factors critical to mediate or
enhance their neurotoxicity is not surprising. Many studies showed that Aβ and tau
concentrations used to induce neuronal damage or death in vitro are often orders of
magnitude higher than those found in vivo[16, 250, 251]. In addition, Aβ and tau
concentrations or plaque and tangle size in vivo are often not correlated with the extent of
neurodegeneration or cognitive decline[16]. Recently, extracellular vehicles (EVs),
exosomes or microvesicles, were proposed as carrier for transport and uptake of Aβ and
tau into neurons[190, 202]. However, it is not clear how this uptake may lead to
neurodegeneration in AD. In this study, we show for the first time that exosomes are not
only carrier for Aβ, but also sensitize neurons to Aβ toxicity. Several studies showed that
plasma or serum from AD mice and patients contains exosomes that are associated with
Aβ, demonstrating that Aβ-associated exosomes crossed the blood brain barrier
(BBB)[217, 252]. In AD patients, about 23% of these exosomes were found to be derived
from astrocytes, while the remainder was from neurons. Association of astrocyte-derived
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exosomes (termed astrosomes in the current study) with Aβ42 was shown to be severalfold higher than that of neurons, suggesting that the primary source of Aβ-associated
exosomes are astrocytes[253]. It was not investigated, however, if Aβ-associated
astrosomes were enriched with ceramide or taken up by cells and involved in the
pathophysiology of AD. Using a method developed in our laboratory, lipid-mediated
affinity chromatography (LIMAC) of vesicles with anti-ceramide antibody[254], we
showed for the first time that astrosomes from serum were ceramide-enriched and
associated with Aβ. Nano- particle tracking analysis (Zetaview) of LIMAC fractions
showed that 9.2% of serum-derived exosomes were Aβ- associated astrosomes, while the
remainder (not bound by anti-ceramide antibody) were only weakly labeled for GFAP
and likely of neuronal origin. The Aβ content in these vesicles was approximately 25 pg
Aβ42/1012 exosomes, which corresponded to 250 μl of serum (5xFAD mice). Mass
spectrometric (LC-MS/MS) analysis of serum-derived exosomes showed enrichment with
ceramide species similar to those found in exosomes released by primary cultures of
astrocytes in vitro[164]. This data prompted us to hypothesize that serum- derived
astrosomes associated with Aβ by a mechanism similar to that previously published for in
vitro generated astrosomes.
In previous studies, we showed that anti-ceramide antibody prevented association
of Aβ42 with in vitro generated astrosomes [226]. We concluded that ceramide was critical
for binding of Aβ42 to astrosomes, by either directly interacting with it or facilitating
interaction of Aβ with other components of the vesicle membrane. In this study, we tested
a novel concept using ceramide analogs originally developed in our laboratory to disrupt
binding of Aβ to astrosomes[255]. The novel ceramide analog N-oleoyl serinol (S18)
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reduced the average diameter of exosomes from 5xFAD mice. This result suggests that
S18-treated exosomes are less prone to aggregation, and probably, association of Aβ with
exosomes is resolved.
To date, only a few studies addressed a potential function of Aβ-associated
exosomes in AD. It was shown that exosomes can spread amyloid between neurons and
that uptake of EVs isolated from the cerebrospinal fluid or plasma of AD patients impairs
mitochondrial respiratory function and induces caspase activation [190, 202]. However, it
was not shown that Aβ-associated astrosomes are ceramide-enriched, transported to
mitochondria, and mediate Aβ-binding to a critical mitochondrial protein. Our previous
studies suggested that Aβ-associated astrosomes induce nucleation of amyloid plaques and
critically participate in neurodegeneration [256]. However, consistent with other reports
showing that neurotoxicity is not directly correlated with plaque size, we hypothesized that
Aβ-associated astrosomes mediate neurotoxicity by a mechanism distinct from plaque
formation. The results using exosomes from serum of 5xFAD mice and AD patients show
that Aβ-associated astrosomes are transported to mitochondria. This is demonstrated by
colabeling of Aβ and ceramide with Tom-20 in cells that are also positive for GFAP and
flotillin 2 when exposed to serum exosomes from 5xFAD mice or AD patients, but not
from wild type mice or healthy controls. These cells show mitochondrial damage as
documented by clustering of mitochondria and increased levels of the mitochondrial
fission protein Drp-1. Our data is consistent with that from previous studies reporting that
the level of Drp-1 is elevated in AD brain and neurons exposed to Aβ in vitro [257, 258].
In our previous studies, we showed that Aβ exposure leads to mitochondrial malformation
and dysregulation of VDAC1, the main ADP/ATP transporter in the outer mitochondrial
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membrane the level of which is elevated in AD[92, 101, 241, 259]. Our data is consistent
with that from previous studies reporting that Aβ binds to VDAC1 and induces formation
of a pro-apoptotic pore [260]. Using cortical protein lysates from AD patient and AD
mouse model brains, it was shown by co-immunoprecipitation assay that Aβ binds to
mitochondrial VDAC1[99]. However, none of the previous studies investigated the effect
of Aβ-associated exosomes on VDAC1 and its interaction with Aβ.
To test the role of Aβ-associated exosomes in the interaction of VDAC1 with Aβ
we performed proximity ligation assays (PLAs) after exposure of N2a cells and neurons
to exosomes from 5xFAD mice and AD patients as well as wild type mice and healthy
controls. Our results show that exosomes from 5xFAD mouse or AD patient serum lead to
PLA signals indicating formation of a complex between VDAC1 and Aβ. Therefore, we
concluded that Aβ-associated exosomes induced or mediated complex formation be- tween
VDAC1 and Aβ. Currently, we are investigating the mechanism by which exosomes
induce this complex formation. Figure 2.11 shows a model for endocytotic uptake and
interaction with VDAC1 at mitochondria mediated by Aβ-associated astrosomes. Aβassociated astrosomes may either be endocytosed as vesicles or first fuse with the plasma
membrane. In both cases, Aβ (red in Fig. 2.11) remains associated with ceramide (green
in Fig. 2.11), probably in the form of ceramide-rich platforms, a type of lipid rafts enriched
with ceramide[144]. The persistent association with ceramide explains why Aβ and
ceramide remain colabeled after uptake of Aβ-associated exosomes into N2a cells and
neurons. Next, Aβ is shuttled to mitochondria, which is probably mediated by vesicular
transport, either by Aβ-associated endosomes or other types of vesicular compartments
such as aberrant autophagosomes[228, 261-263]. Finally, Aβ is imported into
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mitochondria to interact with VDAC1, which induces a pro-apoptotic pore that leads to
release of cytochrome c and activation of caspases [260]. While interaction of Aβ with
VDAC1 and formation of the pro-apoptotic pore was reported, the role of ceramide and
exosomes in this process has not yet been investigated.
Ceramide was invoked in neuronal Aβ release and formation or secretion of
exosomes from astrocytes[226, 229, 256, 264]. Our studies showed that ceramide is
instrumental for interaction of Aβ with astrosomes. In the novel mechanism depicted in
Fig. 2.11, ceramide may critically participate in several steps of uptake, transport, and
mitotoxicity of Aβ. Firstly, association of Aβ with ceramide in the astrosomal membrane
may induce a specific Aβ isoform or aggregate promoting endocytosis. This hypothesis is
consistent with our observation that a proportion of exosomes from serum of 5xFAD mice
or AD patients form aggregates. Secondly, ceramide may critically participate in neuronal
endocytosis and transport of Aβ to mitochondria. In numerous studies, it was shown that
fluorescently labeled ceramide was taken up by endocytosis and then transported to
specific compartments, mainly the Golgi apparatus[265-267]. Albeit the reason for Golgi
accumulation is unclear, other studies support the idea that ceramide guides transport of
endosomes to specific compartments, which may include those interacting with
mitochondria[268, 269]. It should be noted that our previous studies showed that uptake
of Aβ42 by glial cells is reduced by at least 50% when associated with exosomes,
suggesting that uptake of Aβ-associated exosomes as observed in our current study is
specific for neurons and potentially mediated by ceramide[256]. Thirdly, ceramide may
participate in import of Aβ into mitochondria, e.g., by fusing Aβ-associated astrosomes to
the outer mitochondrial membrane, and binding to VDAC1. Interaction of either ceramide
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or Aβ with VDAC1 was demonstrated by several studies from our and other
laboratories[91, 99, 100, 241]. Alternatively, membranes closely associated with the outer
mitochondrial membrane such as mitochondria-associated membranes (MAMs) may take
part in the interaction of Aβ with VDAC1. Fourthly, ceramide may facilitate formation of
a pro-apoptotic pore that is associated with the VDAC1-Aβ complex. VDAC1 oligomers
as well as ceramide channels were reported to partake in pro-apoptotic pores at
mitochondria[97, 270], however, the involvement of Aβ- associated and ceramideenriched exosomes in formation of these pores was not discussed yet. Our observation that
VDAC1-Aβ complexes are colocalized with ceramide at mitochondria suggests a novel
mechanism by which association of VDAC1 with ceramide and Aβ induces or facilitates
pro-apoptotic pore formation. Finally, since association o Aβ with exosomes is remarkably
stable and persists during passage through the BBB into the blood stream, the proportion
of Aβ-associated exosomes may participate in systemic distribution and potentially,
reuptake of Aβ and its spreading throughout the brain.
Our data show that 5xFAD brain-derived and ceramide-enriched exosomes are
neurotoxic and serum contains a proportion of these exosomes crossing the BBB.
However, it is conceivable that these exosomes acquire additional toxic factors during their
passage through the blood stream. Therefore, Aβ-associated exosomes in serum may not
only be a biomarker and “window” to the brain, but actively participate in spreading AD
pathology and contributing to Aβ neurotoxicity after reuptake into the brain. While we
utilized serum-derived exosomes in our in vitro experiments to elucidate the proposed
mechanism, studies are planned to further test the significance of ceramide-enriched
exosomes for Aβ neurotoxicity in vivo. These studies will address the function of different
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ceramide species in neurotoxicity, particularly when comparing 5xFAD mice with AD
patients and the in vivo significance of systemic distribution and reuptake of Aβ-associated
astrosomes. Here we present for the first time experimental evidence for our hypothesis
that ceramide and Aβ act synergistically to target VDAC1 and induce caspase activation,
ultimately leading to neuronal malfunction and apoptosis. Therefore, Aβ-associated
astrosomes assisting in Aβ uptake, transport, and mitotoxicity are a novel key factor in
sensitizing neurons to Aβ and a potential pharmacological target to prevent
neurodegeneration in AD.
Current pharmacological approaches exclusively aim at interfering with ceramide
generation using inhibitors for enzymes in ceramide metabolism [226, 270-272]. The most
prominent example is GW4869, an inhibitor for neutral sphingomyelinase 2 (nSMase2)
we have shown to reduce plaque formation and improve cognition in male 5xFAD mice
[226]. We previously reported that the nSMase2- deficient 5XFAD mice (fro;5XFAD)
showed a reduced number of brain exosomes, ceramide levels, glial activation, total Aβ42
and plaque burden, and improved recognition in a fear-conditioned learning task]. In future
studies, we will specifically address the function of astrocyte-derived exosomes in Aβ
neurotoxicity by including mice with astrocyte-specific deletion of nSMase2 as well as
knockouts of individual ceramide synthases.
While enzyme inhibitors are promising as lead compounds interfering with
ceramide metabolism in AD, alternative pharmacological approaches targeting ceramide
but not depending on enzyme inhibition may offer additional benefits. About 20 years ago,
our laboratory designed and synthesized novel ceramide analogs of the β-hydroxy
alkylamine type, particularly N-oleoyl serinol [273] (S18) that do not inhibit ceramide
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generation, but interfere with binding of ceramide to its protein interaction partners such
as atypical protein kinase C λ/ξ [273]. These analogs were shown to be non-toxic to normal
cells, but induce apoptosis in cancer cells[255]. We hypothesized that novel ceramide
analogs may also interfere with binding of Aβ to ceramide in astrosomes, thereby
providing a novel therapeutic approach preventing astrosome-mediated spreading and
uptake of Aβ, and sensitization of neurons to Aβ. Our data with S18 obliterating exosome
aggregates in 5xFAD serum support this hypothesis, which will also be investigated in our
future research. In summary, our data show for the first time that astrosomes sensitize
neurons to Aβ and suggest that interfering with binding of Aβ to astrosomes using novel
ceramide analogs may provide a novel therapeutic strategy for treating AD.
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Figure 1.15: Potential mechanism of neurotoxicity induced by Aβ-associated
astrosomes. Aβ secreted by neurons (red) binds to ceramide-enriched exosomes secreted
by astrocytes (astrosomes, green). Aβ-associated astrosomes are endocytosed by neurons
and transported to mitochondria. The vesicles fuse with the outer mitochondrial membrane
and mediate binding of Aβ to VDAC1. A pro-apoptotic pore, probably associated with
ceramide, is formed which leads to activation of caspases and induction of neuronal cell
death

73

CHAPTER 3. IN VIVO EVIDENCE OF EXOSOME-MEDIATED AΒ
NEUROTOXICITY
3.1

Introduction
Alzheimer’s disease (AD) is the most prevalent form of dementia in elderly

patients[274]. Amyloid beta (Aβ) is one of the most studied contributors to AD pathology,
however, the intracellular toxicity mechanism of Aβ is not clear yet. Recently, a wealth of
publications has demonstrated ways by which exosomes could participate in the pathology
of AD either in a protective manner or as a facilitator for plaque deposition and shuttling
of misfolded protein[184, 190, 203, 275, 276]. In our recent work, we showed that serum
from the transgenic mouse model of familial AD (5xFAD) and AD patients as well as
5xFAD brain-derived exosomes contains exosomes that are associated with Aβ. The
association with exosomes was shown to substantially enhance Aβ neurotoxicity in AD.
When taken up by neurons in vitro, these Aβ-associated exosomes were transported to
mitochondria, induced mitochondrial clustering, and upregulated the fission protein Drp1. Aβ-associated exosomes mediated binding of Aβ to voltage-dependent anion channel
1(VDAC1) and subsequently, caspase activation. Aβ-associated exosomes also induced
neurite fragmentation and neuronal cell death. However, despite solid and convincing
results, our study lacked the in vivo component. Here, we aim to augment the significance
of our previous experiments by adding in vivo data that confirms our previous results.
Exosome secretion from multiple CNS cell types has been well established in
vitro, besides, the detection of exosomal markers from human cerebrospinal fluid (CSF)
samples indicates that active secretion of these exosomes in the CNS. However, exosome
signaling in situ in the CNS remains essentially unexplored. Aiming to investigate that in
the context of AD, we first injected brain-derived exosomes from nine months old 5xFAD
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mice into the hippocampus of 3 weeks old mice. Second, we generated an astrocytespecific exosome reporter mouse that secrete GFP labeled exosomes from astrocytes. This
tool allows us to visualize and track the exosomes secreted from astrocytes aiming to
understand their dynamics and elucidate their role in AD pathology.

3.2

Methods

Animals: The CD63-GFPf/f knock-in mice were obtained from Dr. Yongjie Yang in Tufts
University School of Medicine[277]. ALDH1l1-CreERT transgenic, (#031008), WT mice
(C57 BL6 background), and 5xFAD (#34848) were obtained from The Jackson
Laboratory. CD63-GFPf/f and ALDH1l1-CreERT mice were bred to generate ALDH1l1CreERTCD63-GFPf/+ mice. ALDH1l1-CreERTCD63-GFPf/+ mice were then bred with
CD63-GFPf/f to generate ALDH1l1-CreERTCD63-GFPf/f mice which was bred with
5xFAD mice. Breeding continued until 5xFAD-ALDH1l1-CreERT-CD63-GFPf/f mice
were generated. Mice were kept on a 12 h light/dark cycle with food and water ad libitum.
Animal protocols used in this study has been approved by the University of Kentucky
IACUC committee.

Drug administration: 4-hydroxytamoxifen (4-OHT) (Sigma) was prepared at 5 mg/mL in
Corn oil at was given to animal at a concentration of 20mg/kg. 4-OHT was given
intraperitoneal for 5 consecutive days. Mice were kept on heating pads for 30 min after
injections. Mice were sacrificed two weeks after the last injections.
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Brain exosome isolation: Nine months old 5xFAD mice were anesthetized using isoflurane
inhalation in a chamber followed by perfusion of the whole body with cold 1x PBS using
Watson-Marlow pump to remove blood- derived exosomes from the brain. Mice brains
were collected, washed with 1x PBS and cut into eight sagittal slices using sterile scalpel
in a petri dish. Brain slices were then transferred to C tubes containing enzymatic
dissociation buffer. C tubes were tightly closed and attached upside down onto the sleeves
of the gentleMACS Octo dissociator with Heaters, Program 37C_ABDK_01 being used.
Samples were resuspended and applied to a MACS SmartStrainer (70 μm) placed on a 50
mL tube. 10 mL of cold D-PBS were applied onto the MACS SmartStrainer (70 μm). Cell
suspensions were centrifuged at 300×g for 10 min at 4 °C, supernatants were carefully
transferred to a fresh tube and supplemented with cocktail protease inhibitor (Halt™
Protease Inhibitor Cocktail, Thermo Scientific) to proceed with exosome isolation.
Supernatants were centrifuged at 2000×g for 10 min followed by 10,000×g for 30–40 min
then passed through a 0.45 μm filter before following the Exoeasy exosome isolation
protocol following the manufacturers steps.

Tissue preparation and sectioning: Two weeks after the last 4-OHT injection and 48 hours
after injection of labeled exosomes, recipient mice were euthanized, decapitated, and
brains were collected. Brains were fixed in 4% paraformaldehyde overnight, then brains
were moved to 15 mL conical tubes containing 30% sucrose. After the brains sank to the
bottom of the tubes, they were collected, dried, and immersed in O.C.T compound in
freezing molds. Bains were then slow-frozen using isopentane and liquid nitrogen. First,
liquidnitrogen was put in a styrofoam box. Isopentane (Fisher Scientific, Cat#O3551-4)
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was poured in a metal canister to a height of 2” and the metal canister was put into the
liquid nitrogen. The two liquids were allowed to equilibrate for 10 minutes, then freezing
molds containing tissues in O.C.T were immersed half-way until evenly frozen. Frozen
blocks were kept in dry ice before transfer to -80 °C. Blocks were sectioned using Leica
cryostat (CM1510, Leica) at temperature of -20 °C and thickness of 12-15ϻm, eight
sections were obtained from each injected mouse around site of injection.

Immunohistochemistry: Sections were retrieved from -20 °C and allowed to dry for 15-30
min. Hydrophobic marker was used to encircle the sections, before rehydrating them in
PBS. Sections were fixed with 4%PFA at 4°C for 10 min, then washed with PBS twice for
5 min. Blocking was done in 3% BSA in PBS for 30 min at room temperature, followed
by primary antibody incubation for 2h at room temperature in incubation buffer (0.3%
BSA in PBS) overnight at 4°C. Primary antibodies used were: anti-cleaved caspase-3
rabbit IgG (Cell Signaling, Danvers, MA, USA, #9664), anti-Tom 20 rabbit IgG (1200,
Santa Cruz, sc-11415), anti-GFAP mouse IgG (1:500, abcam, Cambridge, MA, USA,
ab10062). Sections were then washed 3x for 10 min with PBS, PBS-T, PBS. Secondary
antibody incubation was done at room temperature for 1h in 0.3% BSA in PBS. Sections
were washed 3x for 10 min each, and mounted with Fluoroshield™ with DAPI (F6057,
Millipore-Sigma) or stained with NeuroTrace™ (N21479- Thermo Scientific).
NeuroTrace™ was allowed to warm to room temperature, vortexed briefly, and then
briefly centrifuged to deposit the DMSO at the bottom. Slides were soaked for 10 minutes
in PBS + 0.1% Triton X-100, followed by two rinses in PBS, 5 min each. NeuroTrace was
diluted 1:100 in PBS. 200- 250 uL were applied to each section. Slide were incubated at
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room temperature for 60 min. NeuroTrace was removed and sections were washed for 10
minutes in PBS + 0.1% Triton X-100, followed by soaking in PBS twice for 5 min.

Proximity ligation assay: Tissues were prepared as mentioned earlier and incubated with
primary antibodies overnight at 4°C. The primary antibodies used were: anti-Aβ mouse
IgG (1:500 4G8, Biolegends, California, USA, SIG-39220), anti-VDAC1 rabbit IgG
(1:1000 abcam, Cambridge, MA, USA, ab34726). Secondary PLA probes: anti-mouse
MINUS affinity-purified donkey anti-mouse IgG (H + L) and anti-rabbit PLUS affinitypurified donkey anti-rabbit IgG (H + L) were diluted 1:5 in antibody diluent buffer and
samples incubated for 1 h at 37 °C followed by ligation and amplification steps as
described in the manufacturer’s protocol (Duolink, Sigma-Aldrich). Sections were
mounted using Fluoroshield supplemented with DAPI (Sigma-Aldrich) to visualize the
nuclei.
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3.3

Results
Firstly, labeled 5xFAD exosomes are taken up by neurons in WT mouse brain

as denoted by the presence of Vybrant Cm DiI labeled exosomes inside Neurotrace
positive cells (Fig. 3.1c). Interestingly, WT exosomes were taken up to a lesser extent (Fig.
3.1b). Next, we labeled brain sections for both the mitochondrial protein Tom-20 and
Neurotrace to investigate the shuttling of exosomes to mitochondria as determined in our
in vitro experiments. As expected, we found solid colocalization between 5xFAD-derived
and labeled exosomes and Tom-20 inside neurons (Fig. 3.2a), which was also detectable
with WT exosomes, but to a lesser extent. In order to investigate the subsequent
mechanism of this interaction between mitochondria and exosomes, we performed
proximity ligation assay using antibodies against Aβ and Voltage-dependent anion channel
1 (VDAC1), the main ADP/ATP transporter in the outer mitochondrial membrane. We
found positive signals (denoted by green dots) inside neurons of brains injected with
5xFAD exosomes, but not in the brains injected with WT exosomes (Fig. 3.3a, b),
suggesting that Aβ was shuttled via these exosomes to neurons and associated with
mitochondrial VDAC1. Moreover, the association of 5xFAD exosomes and Aβ lead to
caspase activation in neurons as demonstrated by the presence of cleaved-caspase signal
in neurons that took up 5xFAD exosomes, which was not observed when injecting WT
exosomes (Fig. 3.3c, d).
Using our astrocyte-specific exosomes reporter mouse, we show the first in-situ
evidence that CD63 positive exosomes are secreted from astrocytes (Fig.3.4). Similar to
the injected exosomes, these exosomes are taken up by neurons, which provide a clear
evidence of communication between astrocytes and neurons via exosomes (Fig.3.5). The
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astrocytes-derived exosomes also associate with mitochondria as noted by colocalization
between the exosomal endogenous GFP and mitochondrial Tom-20 (Fig. 3.5).
Interestingly, a subpopulation of the astrocyte-derived exosomes shuttled Aβ to neurons,
confirming our in vitro as well as injected 5xFAD data.
In conjunction with our previous data, these results demonstrate the relevance of
exosomes in Aβ induced neurotoxicity in vivo, suggesting that disruption of Aβ association
of exosomes offers a new therapeutic approach to AD.

Figure 3.1: 5xFAD exosomes are taken up by WT neurons in vivo. (a) A schematic
diagram of the experimental design. Exosomes isolated from brains of 5xFAD mice were
first labeled with lipid-binding dye Vybrant CM DiI before being injected intracranially
into wild type (WT) mice. Forty-eight hours post-injection, mice were sacrificed, and
brains were collected and prepared for cryo-sectioning. (b, c) Representative
immunocytochemistry images of sections of brains injected with (b) WT exosomes and (c)
5xFAD exosomes showing that FAD exosomes are internalized by WT neurons, insert is
a higher magnification of the selected ROI
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Figure 3.2: 5xFAD exosomes associate with neuronal mitochondria: (a) Representative
confocal images of brain section showing that FAD exosomes (red) are colocalized with
Tom-20 (green) inside neurons (blue). Insert is a 3D rendering of the selected ROI.
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Figure 3.3: 5xFAD exosomes associate with neuronal mitochondria VDAC1 leading
to caspase activation. Representative photomicrographs of (a) WT exosomes and (b)
5xFAD exosomes injected in brains of WT mice showing PLA complex formation (green)
inside neurons (blue) in brains injected with 5xFAD exosomes. (c) WT exosomes injection
showing no caspase activation, while (d) shows 5xFAD exosome- injected brains showing
positive cleaved caspase-3 signals (green) colocalized with labeled exosomes (red).
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Figure 3.4: In situ illustration of astrocyte-secreted exosomes internalized into
neurons. Representative confocal images of the CD63-GFP+ (green) secreted from
astrocytes (red) and being taken up by nearby neurons(blue).
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Figure 3.5: Astrocyte-secreted exosomes associate with mitochondria inside neurons.
(a)Representative confocal image and 3D rendering(b) showing colocalization between the
CD63-GFP+ (green) secreted from astrocytes (red) and Tom-20 (red) inside neurons.

84

Figure 3.6: In situ evidence that astrocyte-secreted exosomes shuttle Aβ to neurons.
(a)Representative confocal images showing colocalization between Aβ(red) and the
astrocytes-secreted exosomes (green) in close proximity to senile plaque(a) or in plaquefree region (b).
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CHAPTER 4. DISCUSSION

During the past two decades, only one drug has been approved for Alzheimer’s
treatment, which is the NMDA antagonist memantine[278].Numerous potential drugs and
clinical trials have failed, leaving AD patients with only four valid treatments. So far,
nearly all clinical trials are directed to a single aspect of the disease. These aspects include
but are not limited to; fluctuations between removing or preventing aggregation of Aβ,
inhibiting BACE, induction of ketosis, Serotonin reuptake inhibition and tau stabilizing.
To date, none of these sole targets are able to give a complete resolution to the AD
pathology. This is mainly because AD is not a simple disease with one target, but rather a
complex multifactorial disease involving different cell types and numerous feedback and
forward mechanisms throughout its progression, not to mention the enclosed environment
where it occurs, adding an extra layer of complexity to the disease.
Astrocytes represents the most abundant glial cells in the central nervous
system[279]. Under normal physiological conditions, they play key roles in brain
development and function. Through their extended processes, astrocytes can contact other
glial cells, synapses, and blood vessels which allow them to participate in several aspects
of synapses maturation and formation, release and uptake of neurotransmitters, trophic
factors production, and control of neuronal survival. Astrocytes were initially thought of
as a homogenous population of cells, however, a wealth of reports indicated high levels of
astrocyte’s

heterogenicity, both

functionally
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and

morphologically.

Astrocyte’s

heterogenicity could be observed localized to a certain area of the brain or generalized
across brain regions[280].
There are two major subtypes of astrocytes: fibrous and protoplasmic. The fibrous
astrocytes are normally prevalent within white matter and are characterized by smaller
body size and less branches compared to protoplasmic astrocytes, allowing them to make
contact with nodes of Ranvier aiding in maintaining homeostasis. The protoplasmic
astrocytes are the most prevalent astrocytes in the grey matter. Their cell bodies are
ramified, allowing them to interact with several synapses simultaneously and they are
mostly found in the cerebral cortex and hippocampus[281].
In the context of AD, the likelihood of astrocytes involvement in the disease
pathology was reported by Alios Alzheimer when he described the association between
senile plaques and glial cells in brain tissues. However, the AD research field has focused
primarily on Aβ and tau, while the glia research only gained momentum thanks to the
recent GWAS discovery of several risk loci in genes related to the innate immune system,
as well as the recent report implicating astrocytes and microglia in synaptic activity
modulation and pruning. In AD brain samples, senile plaques are decorated with reactive
astrocytes and activated microglia, however, the role of reactive astrocytes stirred
controversy. Upon exposure to several stimuli, including Aβ in AD, astrocytes acquire a
reactive or activatedphonotype. This activation state is manifested through hypertrophy of
cellular processes, elevated GFAP expression, release of cytokines and interleukins, and
increased exosomes secretion[282]. Similar to macrophages, activated astrocytes seems to
be polarized into two phenotypes: A1 and A2. While A2 are viewed as protective reactive
astrocytes known to secrete neuroprotective cytokines, A1 represents the neurotoxic
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phenotype that lost their protective capacities and are known to upregulate a number of
proinflammatory genes that have been reported to be destructive to synapses[282]. It is
widely accepted that in AD and other neurodegenerative diseases that A1 astrocytes are
the most abundant form, prompting researchers to study the toxic effect of those astrocytes
in different diseases.
Recently, extracellular vesicles and exosomes, in particular, have emerged as
contributors to the progression of disease, tools of analysis, and potential therapeutic
targets[276]. Several groups reported exosomes to be transporters of Aβ, and this complex
has been shown to be up taken by neurons as well as crossing the blood brain barrier.
Astrocytes derived exosomes have emerged as a recent area of interest for many groups,
given the crosstalk, direct and indirect interactions between different cells types in the
brain, astrocytes-derived exosomes seemed a good candidate to study their participation
in the disease pathology.
Within this perspective, our group was among the first to describe that reactive
astrocytes’ increased exosomes secretion upon exposure to Aβ. First, Wang et al. described
the secretion of ceramide-rich exosomes from primary cultured astrocytes when
challenged with Aβ. Not only that these exosomes were toxic to recipient astrocytes, but
they also carried the prostate apoptotic protein 4 (PAR-4), however, this effect was not
tested on neurons[164]. Next, astrocyte-derived exosomes were shown to promote Aβ
aggregation in vivo and in vitro. This aggregation was diminished when ceramide antibody
was added to the mixture. In vivo, chemical and genetic inhibition of nSMase2 lead to the
reduction of exosome secretion, concomitant with the reduction of total Aβ and senile
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plaques numbers, connecting ceramide-enriched exosomes to Aβ transfer and
aggregation[226, 256].
Clearly, transferring Aβ to other cells or plaques and being toxic to recipient
astrocytes are two distinct attributes of astrocyte-derived exosomes. With regards to Aβ,
the previous understanding was that astrocytes-derived exosomes exert their harmful effect
through inhibiting the uptake of Aβ by glial cells, leading to decreased clearance and
facilitating Aβ aggregation. However, given the growing notion fueled by several reports
that the size and number of amyloid plaques does not necessarily correlate with cognition
deterioration in aging AD patient, we hypothesized that astrocytes-derived exosomes are
mediators of the Aβ toxicity rather than merely adding them to the plaques.
In our first aim, we were concerned with the biophysical and biochemical
characteristics attributed to 5xFAD exosomes compared to the WT littermates. As
mentioned earlier, exosomes have the capability to freely cross the BBB. Knowing this,
we used serum derived exosomes as a window to the brain.
The first difference we noticed was in the mean diameter of 5xFAD exosomes
compared to the WT exosomes. While running Zetaview analysis, 5xFAD exosomes size
distribution curves presented a distinct “shoulder”-containing patterns that were
notobserved in the WT samples. Further clustering analysis identified an additional
population in the 5xFAD exosomes with relatively higher diameter that was not present in
the WT samples. The presence of this additional subpopulation means either that those
exosomes are simply larger in diameter or they are more prone to aggregation. The
difference in diameter lead us to question the lipid composition of the 5xFAD as a driving
factor for such difference. Indeed, mass spectrometry revealed a significant enrichment in
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certain ceramide species in the 5xFAD compared to the WT exosomes including C18:0,
C24:0 and C24:1. The enrichment of these specific ceramide species in 5xFAD serum
derived exosomes goes in line with other reports linking the higher levels of these species
to several aspects of aging and neurodegenerative disease[153]. The ceramide enrichment
was also observed in AD patients’ serum derived exosomes compared to healthy control.
While total ceramide levels were higher in both 5xFAD exosomes and AD patients’
exosomes, the elevated ceramide species showed some discrepancies between 5xFAD and
human samples. One explanation for that could be different levels of activity of certain
ceramide synthases between the two biological systems. Since we are interested in the
ceramide enriched exosomes, we used a lipid-mediated affinity chromatography (LIMAC)
technique with anti-ceramide antibody in order to separate ceramide-enriched exosomes
from the exosome’s pools. Using that method, we showed for the first time that astrocytes
derived exosomes are enriched in ceramide and carry Aβ as cargo. This supports our
previous in vitro findings that ceramide is essential for the binding of Aβ to astrocytesderived exosomes. Microscopy techniques using N2a cells as well as primary culture
neurons, incubated with either 5xFAD and AD patients’ serum exosomes, confirmed that
astrocytes-derived exosomes are enriched in ceramide and shuttle Aβ into neurons.
As mentioned in chapter 1, the association between Aβ, and exosomes in general,
has been reported by several groups[183, 190, 203, 208, 276, 283]. Similarly, the presence
of Aβ in astrocytes-derived exosomes either in vitro or from AD patient’s serum/plasma
has previously been described as well[214, 215, 218-220]. However, the biological
functions of the astrocytes-derived Aβ-harboring exosomes have not yet been clarified yet.
Taking our study further, we aimed to investigate the intracellular target of our astrocytes-
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derived exosomes inside neurons. One of the target organelles was mitochondria, since our
group previously showed that cultured astrocytes when treated with Aβ secrete astrocytesderived exosomes that induce apoptosis in recipient astrocytes. While studying the
colocalization between astrocytes-derived exosomes and mitochondria, we noticed that
5xFAD astrocytes-derived exosomes caused mitochondrial clustering in N2a cells, this
observation was absent in WT treated cells. Following up on that, we reported elevated
levels of expression of DRP1, a key protein in regulating mitochondria fission. High levels
of DRP1 indicated excessive mitochondrial fission, leading to mitochondria fragmentation
that renders mitochondria dysfunctional. We next show that Aβ, carried on 5xFAD
astrocytes-derived exosomes, directly interacts with mitochondrial VDAC1 using
proximity ligation assay. This was concomitant with upregulation of cleaved caspase and
subsequently induction of apoptosis, which presents a potential mechanism by which
astrocytes-derived exosomes enhance the neurotoxicity of Aβ in AD.
One area of significance pertaining to this dissertation work stems from its
potential to solve a huge dilemma in the AD research field while conducting Aβ-induced
toxicity experiments. The exact identity of the most toxic form of Aβ is not known yet,
presenting a significant knowledge gap in the field. A multitude of Aβ forms have been
described in literature, and due to their heterogeneity and metastability, it is elusive which
ones are relevant to AD pathology and which are simply experimental artifacts[284, 285].
This lack of information has unfavorable consequences in many areas. First, it is
almost unachievable to predict which target is being engaged by antibody-directed
therapeutics. Second, it is impossible to interpret data and compare results between
different groups knowing that there is not a set of commonly agreed-upon experimental
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conditions using the same form of toxic Aβ. The third aspect is concerning the
concentration at which Aβ is used in toxicity experiments. Several studies provided
different mechanisms of Aβ-influenced neuronal toxicity, however, the used Aβ
concentrations are significantly higher than the reported physiologic levels of Aβ in AD
patients’ CSF[286, 287]. Interestingly, the astrocytes-derived exosomes - associated Aβ
concentrations used in our experiments are within the femtomolar range as indicated by
ELISA assay. That concentration is an order of magnitude lower than what is reported in
literature, indicating a significant contribution to astrocytes-derived exosomes in
sensitizing neurons to the harmful effect of Aβ. In addition, astrocytes-derived exosomes
-associated Aβ provides a physiologically relevant form of the peptide that is subjected to
minimal experimental alterations, if any, promoting this complex as a potential target for
research and therapeutics.
The colocalization between astrocytes-derived exosomes-bound Aβ with
mitochondrial marker and the direct interaction with VDAC1 raises a few questions. The
first inquiry is regarding the way by which astrocytes-derived exosomes enter the cells.
Several methods of exosome uptake have been reported, including simple diffusion,
pinocytosis, micropinocytosis and clathrin dependent endocytosis[288, 289]. While this
study did not touch on the mechanism of exosomes uptake, another group investigated that
feature with respect to neuronal exosomes carrying Aβ in vitro. They report that the
chemical drug dynasore lead to decreased uptake of exosomes and their Aβ cargo. That
indicates the mechanism is dynamin dependent endocytosis, at least in SY5Y cells[190].
The next question which needs to be answered, is the mechanism by which astrocytesderived exosomes are shuttled and directed to mitochondria specifically. As with the
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uptake of exosomes, the exact route of them in a cell is not an elucidated subject yet.
Several groups studied the effect on exosomes after being taken up via certain
mechanisms. For example, exosomes that are taken up through phagocytosis and
micropinocytosis are doomed to be cleared without having any effect on the recipient cells.
However, exosomes can trigger a cellular response in case of raft-mediated endocytosis,
fusion and juxtacrine or soluble signaling[290]. While that might narrow down the
potential method of uptake and subsequent route of astrocytes-derived exosomes in
neurons, more detailed mechanism needs to be clarified as to how these exosomes end up
in direct interaction with mitochondria.
In addition, while we do show direct association between Aβ in exosomes and
VDAC1, the precise mechanism is not exactly known yet. VDAC1 regulates a variety of
cell functions and could be affected by a myriad of compounds, molecules and miRNAs.
We show that apoptosis is the end result of the Aβ/VDAC1 interaction, however, more
work needs to be done to further delineate the exact mechanism of this effect.
In that regard, ceramide may influence several aspects of our proposed mechanism.
The enrichment of ceramide in the astrosomal membranes might play a role in conferring
stability to these vesicles, leading to the facilitation of their binding or uptake in neurons.
Also, the presence of ceramide within lipid raft might aid in the uptake process of Aβ as
well. This synergestic effect of ceramide could occur by direct interaction with Aβ or
facilitating its interaction with other components of the vesicle membrane, resulting in
stabilizing the Aβ or inducing a specific Aβ isoforms that favor cell interaction. Moreover,
ceramide might actively participate in neuronal endocytosis and transport of Aβ to
mitochondria, given ceramide’s ability to bind to several proteins that help directing it to
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specific cellular compartment. Lastly, Due to the knowledge that ceramide interacts with
VDAC1, it is conceivable that ceramide might strengthen the interaction between Aβ and
VDAC1 or act as a facilitator and/or stabilizer for that binding.
Aiming to tackle some of these questions, we used a novel ceramide analog,
particularly N-oleoyl serinol (S18), to interfere with the binding of Aβ to astrocytesderived exosomes. The S18 ceramide analog reduced the average diameter of exosomes
from 5xFAD mice. In addition, pre-incubation of 5xFAD exosomes with S18, prior to
neuronal treatment, led to significantly lower PLA signals of VDAC1/Aβ complex. This
suggests that S18 rendered the 5xFAD less prone to aggregation, judging by the decreased
mean diameter of the treated vesicles. Coupled with fewer PLA signals of VDAC1/Aβ
complex, these results indicate that S18 seemingly resolved the association of Aβ with
astrocytes-derived exosomes.
While exosomes have been extensively studied from biological fluids, isolation of
exosomes from the brain tissue is fairly recent. Levy group took the lead in establishing
methods of isolating exosomes from brain tissues, a procedure that is continuously being
modified as it is adopted by other groups[291]. However, those methods utilize
homogenization of tissues and filtration methods that have the potential of compromising
the extracellular environment with intracellular vesicles and exosome-like molecules in
addition to the drawback of the after mentioned procedures being lengthy and technically
challenging. In this work, we have taken a critical approach to isolation of exosomes from
the brain’s extracellular space. As described in section 2, we achieved that utilizing gentle
dissociation of brain tissue using programmed instrumentation (GentleMax, Miltenyi
Biotec) in order to avoid the presence of unwanted contaminants in our preparations. After
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removing the cells, we subject the diluted extracellular fluid to a series of centrifugations
followed by filtration before carrying exosome isolation using the commercially available
ExoEasy kit. At this stage, we provide a new method for exosome isolation from either
fresh or frozen brains, which is reliable, easy to carry out, and not time consuming. More
importantly, this method preserves the integrity of exosomes and their carried cargo as
confirmed via characterization of their size, morphology, and protein content.
Using this method, we isolated exosomes from 5xFAD and WT littermates’ brains
and repeated our experiments to study whether brain-derived exosomes would act
similarly as serum derived exosomes. As expected, we found that 5xFAD exosomes
showed higher levels of expression of GFAP and are significantly more toxic compared to
WT ones. 5xFAD brain exosomes were shown to be apoptotic to neurons using FLICA
assay, which detects early caspase activation in live cells. Interestingly, the toxicity of
5xFAD exosome was greatly mitigated when ceramide-enriched exosomes were pulled
down and removed from the exosomes pool, reinforcing the idea that ceramide is essential
for the harmful effect of exosomes.
Of note, we chose to use 5xFAD mouse model due to its progressive production of
Aβ at early age. However, this mouse model lacks one significant physiologic hallmark of
AD, namely the neurofibrillary tangles. Ptau is known to be spread via exosomes and is
also known to target astrocytes, therefore a mouse model expressing ptau alongside Aβ
might give a more comprehensive idea about the astrocytes-derived exosomes
participation in AD pathology.
In addition, in our experiments we used total brain-derived exosomes and
serum-derived exosomes from transgenic mice and AD patients. While we followed

95

different approaches to discern the astrocytes-derived exosomes part, it might be more
helpful to use exosomes exclusively from astrocytes. While there are reported protocols to
immune capture those desired exosomes from particular cell types including astrocytes,
the problem relies in the yield and the starting material needed for each experiment[218].
So far, immunocapturing exosomes from a single cell type from in vivo origin has been
used in downstream studies concerning nucleic acid determination or proteomic analysis.
Functional studies require higher numbers of exosomes given the heterogeneity of the
effect on neurons, which is important to be noted.
The second aim was to test the neurotoxicity of the Aβ/ astrocytes-derived
exosomes complex with respect to their uptake into neuron and intracellular toxicity
mechanisms, which we already touched upon in chapter 2. Taking that aim further, we
studied the in vivo relevance of our findings that we observed in vitro. Labeled 5xFAD
brain derived exosomes were injected into the hippocampus of two week old WT mice.
5xFAD brain derived exosomes were shown to be preferentially taken up by neurons,
where they associate with mitochondrial VDAC1 and initiate apoptosis. This data
significantly corroborates the in vitro studies, however it does not delineate the origin of
the up taken exosomes.
Aiming to visualize the endogenous exosome transfer from astrocytes to neurons,
we generated a triple transgenic mouse model that secretes GFP-labeled exosomes
exclusively from astrocytes, which allows us to track them and their uptake. As with the
injected exosomes, we found GFP-labeled exosomes inside nearby neurons and around
amyloid plaques. We also found that they associate with amyloid beta and colocalize with
mitochondria. To our knowledge, this work provides the first in vivo evidence of the
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transport of Aβ from astrocytes to neurons via exosome, adding a new layer of complexity
to the AD pathology given the neuroprotective roles attributed to astrocytes in normal
conditions. The significance of these finding relies on the facts the astrocytes are the most
abundant cell types in the brain. Even the slightest contribution to the spreading of the
most toxic form of Aβ could significantly exacerbate the pathology of the disease. This
finding is in accordance with new reports implicating astrocytes in the metabolism and
generation of Aβ.
Questions may arise concerning the origin of the Aβ associated exosomes. While
we focus on astrocytes derived exosomes in this work, it is not to be excluded that other
cell types in the brain secrete exosomes that can associate with Aβ. In fact, most of the
publication regarding Aβ association with exosomes are done in neuronal cultures. Similar
to the distinct cargo depending on the originating cell type, the fate of exosomes and their
uptake by different cell types seems to be governed by their donor cells. For instance,
microglia derived exosomes are thought to play a protective role when it comes to Aβ
handling[292]. Exosomes from microglia mainly bind to Aβ and aid in the clearance of
the peptide, preventing its uptake by neurons. In addition, the specificity of astrocytesderived exosomes uptake by neurons has been independently shown by separate groups
utilizing in vitro models[293]. That prompted us to build on our group’s previous work,
proposing astrocytes-derived exosomes as the main toxic exosomes in the brain.
In conclusion, irrespective of the inherent limitations of our study, our data
advocate that the Aβ/ astrocytes-derived exosomes association is a viable target for
treatment of AD to suppress the Aβ-induced toxicity.
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Genomics,15(2):58.

•

Ahmad S, Fatteh N, El-Sherbiny NM, Naime M, Ibrahim AS, Elsherbini AM,
El-Shafey SA, Khan S, Fulzele S, Gonzales J, Liou GI (2013): Potential role of
A2A adenosine receptor in traumatic optic neuropathy. J of Neuroimmunol,
264(1-2):54-64.

•

Elsherbiny NM, Naime M, Ahmad S, Elsherbini AM, Mohammad S, Fulzele S,
El-Remessy AB, Al-Gayyar MM, Eissa LA, El-Shishtawy MM, Han G, White
R, Haroldo TF, Liou GI (2013): Potential roles of adenosine deaminase-2 in
diabetic retinopathy. Biochem Biophys Res Commun., 436(3): 355-361

•

Elsherbiny NM, Ahmad S, Naime M, Elsherbini AM, Fulzele S, Al-Gayyar MM,
Eissa LA, El- Shishtawy MM, Liou GI (2013): ABT-702, an adenosine kinase
inhibitor, attenuates inflammation in diabetic retinopathy. Life Sci., 93 (2-3): 7888.

B. Local, National, and International Symposia

• Ahmed Elsherbini, Alexander Kirov, Michael B. Dinkins, Sanjib Karki,
Simone M. Crivelli, Haiyan Qin, Zhihui Zhu, Priyanka Tripathi, and Erhard
Bieberich. “Astrocyte-derived ceramide- enriched exosomes (“astrosomes”)
enhance neurotoxicity of Amyloid beta” Southeastern Regional Lipid
Conference Ashville, Nov 2019
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•

Ahmed Elsherbini, Alexander Kirov, Michael B. Dinkins, Sanjib Karki, Simone
M. Crivelli, Haiyan Qin, Zhihui Zhu, Priyanka Tripathi, and Erhard Bieberich.
“Association of Aβ with astrocyte-derived and ceramide- enriched exosomes
mediates Aβ mitotoxicity in neurons which is prevented by novel ceramide
analogs” Society for Neuroscience. Chicago, Oct 2019

•

Elsherbini A, Dinkins M, Leanhart S, Zhong L, Wang G, Jiang X, Zhu Z,
Spassieva S, Qin H, and Bieberich E. “Astrocyte-derived ceramide- enriched
exosomes (“astrosomes”) enhance neurotoxicity of Amyloid beta”

Southeastern Regional Lipid Conference- Cashiers, Sep2018

•

•

A. Elsherbini, A. Kirov, M. Dinkins, S. Leanhart, L. Zhong, G. Wang1, S.
Spassieva, M. Sauer, A. Schubert-Unkmeir, E. Bieberich.“Characterization of
molecular interaction between exosomal ceramide and beta amyloid, revealing a
role of ceramide in Abeta aggregation and toxicity” Society for Neuroscience.
San - Diego, September 2018
Elsherbini, A., Kirov, A., Dinkins, M., Leanhart, S., Zhong, L., Wang, G., Jiang,
X., Zhu, Z., Spassieva, S., Qin, H. Burgert, A., Schubert- Unkmeir, A. , Sauer, M.,
and Bieberich, E.” Characterization of the molecular interaction between
exosomal ceramide and beta amyloid, revealing a role of ceramide in Abeta
aggregation and toxicity.” American Society for Exosomes and
Macrovesicles- Baltimore, October 2018

• Ahmed Elsherbini, Alexander Kirov , Michael Dinkins, Silvia Leanhart ,
Guanghu Wang, Haiyan Qin , Anne Burgert, Markus Sauer , Alexandra
Schubert-Unkmeir, Zhihui Zhu, Stephanka Spassieva , Xue jiang , Lianshing
Zhong, Erhard Bieberich.” Characterization of molecular interaction
between exosomal ceramide and beta amyloid”
•

Jessica L. Pierce, Kanglun Yu, Ahmed Elsherbini, Elizabeth W. Bradley,
Jennifer J. Westendorf, Meghan E. McGee-Lawrence. Osteoblastic Hdac3
Expression Regulates Systemic Energy Metabolism. American Society for
Neurochemistry. Riverside, March2018
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•

Jason Conger, Matt Manning, Ahmed Elsherbini, Brendan ware, Behren
Bass, Patricia Schoenlein. Targeting MEK/MAPK1/2 In- Vivo to Eradicate
Antiestrogen Resistance. The American Society for Bone and Mineral
Research. Atlanta, September 2016

•

Emily Bass, Matt Manning, Ahmed Elsherbini, Brendan Ware, Meghan
McGee-Lawrence, Patricia Schoenlein. HDAC targeting to potentially optimize
BimEL-induced apoptosis in antiestrogen- treated breast cancer cells. Medical
Scholars Research Day. Augusta, September 2015

•

Sadanand Fulzele, Ahmed Elsherbini, Saif Ahmad, Rajini Sangani, Suraporn
Matragoon, Azza El-Remessy, Gregory I. Liou. The microRNA miR-146b-3p
controls diabetic retinal inflammation by suppressing adenosine deaminase2. The Association for Research in Vision and Ophthalmology (ARVO)
annual meeting, Seattle, May2014

3. Talks
• “Ceramide-enriched exosomes enhances neurotoxicity of Aβ in Alzheimer’s
disease” International Society of Extracellular vesicle, Virtual, August 2020.
• “Association of Abeta with astrocytes-derived and ceramide-enriched exosomes
mediates Abeta neurotoxicity” Southeastern Regional Lipid Conference.
Ashville, November 2019.
• ” Characterization of the molecular interaction between exosomal ceramide and
beta amyloid, revealing a role of ceramide in Abeta aggregation and toxicity.”
American Society for Exosomes and Macrovesicles. Baltimore, October
2018.
•

“Astrocyte-derived ceramide-enriched exosomes (“astrosomes”) enhance
neurotoxicity of Amyloid beta” Southeastern Regional Lipid
Conference. Cashiers, Sep2018.
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4. Awards

•

PhD contest finalist, Sphingolipids Biology Seminar Series. Virtual, October 2020.

•

Travel award, Southeastern Regional Lipid Conference. Ashville, November 2019.

•

Travel award, Southeastern Regional Lipid Conference. Cashiers, Sep2018
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